# Chapter 102: Cannabis Withdrawal

# The Biological and Neurological Basis of Cannabis Withdrawal

## Introduction

For many years, the existence of a clinically significant cannabis withdrawal syndrome was a subject of debate (Roy‐Byrne, 2008). However, with the rising potency of cannabis products and an increasing prevalence of regular, high-frequency use, a substantial body of clinical and preclinical research has firmly established Cannabis Withdrawal Syndrome (CWS) as a valid and clinically relevant phenomenon (Ramesh et al., 2011; Connor et al., 2021). The syndrome was formally recognized and included in the fifth edition of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-5), solidifying its place in psychiatric nosology (Thompson & Weber, 2021; D’Arrigo, 2020). CWS is defined by a constellation of distressing physical and psychological symptoms that emerge upon cessation or significant reduction of heavy and prolonged cannabis use (Connor et al., 2021; Thompson & Weber, 2021).

The typical onset of symptoms occurs within 24 to 48 hours of cessation, with a peak intensity between days two and six, and a duration that can extend for several weeks in heavy users (Connor et al., 2021). The most common features include a range of affective and somatic disturbances, such as irritability, anger, or aggression; anxiety and nervousness; sleep difficulties, including insomnia and strange dreams; depressed mood; restlessness; and decreased appetite or weight loss (Ramesh et al., 2011; Thompson & Weber, 2021; Bahji, 2020; Chuen, 2022). Less common physical symptoms may include headaches, sweating, chills, and stomach pain (Connor et al., 2021; Chuen, 2022). In rare cases, abrupt cessation of heavy use has been associated with the emergence of acute psychotic symptoms (Ramos et al., 2022; Chesney et al., 2024; Thomas, 1993).

The clinical significance of CWS is profound, as the discomfort and distress it causes are primary drivers of relapse to cannabis use (Connor et al., 2021; Ramesh et al., 2011). Individuals attempting to quit may resume cannabis use simply to alleviate the aversive withdrawal state, thus perpetuating a cycle of dependence (Bahji, 2020). Furthermore, the symptoms of CWS significantly overlap with those of other psychiatric conditions, particularly mood and anxiety disorders, which can complicate diagnosis and treatment (Connor et al., 2021; Ramesh et al., 2011).

This chapter provides a comprehensive overview of the biological and neurological mechanisms that underlie the cannabis withdrawal syndrome. Far from being a purely psychological phenomenon, CWS is rooted in profound neuroadaptations within the brain's endocannabinoid system and its extensive network of interconnected neurochemical pathways. We will explore the roles of various neurotransmitter systems, key brain regions, and neural circuits that become dysregulated following the cessation of chronic cannabis exposure. Furthermore, we will examine the cellular, molecular, and genetic factors that contribute to individual vulnerability and the heterogeneity of the withdrawal experience. By elucidating the neurobiological basis of cannabis withdrawal, we can better understand its clinical presentation, appreciate its impact on health, and develop more effective, biologically-informed strategies for treatment and relapse prevention.

## Neurobiological Systems

The manifestation of cannabis withdrawal is a direct consequence of the brain's attempt to re-establish homeostasis following a period of chronic and heavy exposure to exogenous cannabinoids, primarily Δ9-tetrahydrocannabinol (THC) (Pytell & Rastegar, 2025; Ramesh et al., 2011). This process involves a cascade of neuroadaptations, beginning with the endocannabinoid system (ECS) itself and rippling outward to modulate a wide array of interconnected neurotransmitter systems and neural circuits responsible for regulating mood, stress, sleep, and reward (Thompson & Weber, 2021). The resulting state is one of widespread central nervous system (CNS) dysregulation, which gives rise to the characteristic psychological and somatic symptoms of withdrawal (Ramesh et al., 2011).

### The Endocannabinoid System: The Primary Substrate of Withdrawal

The ECS is a ubiquitous neuromodulatory system that plays a crucial role in maintaining physiological homeostasis across the body (Chaouloff et al., 2013). In the CNS, the cannabinoid type 1 (CB1) receptor is one of the most abundant G-protein coupled receptors, densely expressed in brain regions that govern memory, cognition, emotion, motor control, and appetite (Dervaux, 2013). THC exerts its psychoactive effects by acting as a partial agonist at these CB1 receptors (Pytell & Rastegar, 2025).

Chronic, high-dose exposure to THC leads to significant neuroadaptive changes within the ECS. The most critical of these is a compensatory downregulation and desensitization of CB1 receptors in multiple brain regions (Ramesh et al., 2011). This reduction in receptor density and signaling efficacy is a homeostatic mechanism designed to counteract the persistent overstimulation by exogenous THC. As a result, the brain becomes dependent on the presence of THC to maintain a semblance of normal synaptic functioning. When cannabis use is abruptly stopped or significantly reduced, the brain is left with a hypofunctional ECS that is no longer sufficiently stimulated by its endogenous cannabinoids (endocannabinoids) (Ramesh et al., 2011). This state of reduced endocannabinoid tone is the primary driver of the withdrawal syndrome, unmasking the dysregulation of numerous downstream neurotransmitter systems that are normally modulated by CB1 receptor activity.

### Dysregulation of Interconnected Neurotransmitter Systems

The symptoms of cannabis withdrawal are not solely attributable to a deficient ECS; they are the direct expression of dysfunction in other major neurotransmitter systems that are under the regulatory influence of CB1 receptors.

**The Stress System and the Hypothalamic-Pituitary-Adrenal (HPA) Axis:**
A core feature of cannabis withdrawal is a profound state of stress, anxiety, and negative affect (Ramesh et al., 2011; Connor et al., 2021). This is biologically underpinned by a hyperactive stress response. The ECS normally exerts an inhibitory tone on the HPA axis, the body's primary stress response system (Wand, 2008). Chronic THC exposure can blunt this system. During withdrawal, the loss of CB1-mediated inhibition leads to a disinhibition of stress pathways, resulting in the hypersecretion of stress-related hormones and neuropeptides like corticotropin-releasing factor (CRF) and glucocorticoids (e.g., cortisol) (Wand, 2008; Os et al., 2004). This hyperactivation of the HPA axis and central stress circuits is a key mechanism driving the anxiety, irritability, restlessness, and dysphoria characteristic of withdrawal (Anisman & Merali, 2003; Wand, 2008). This state of physiological and psychological distress is a potent motivator for relapse, as re-administration of cannabis can temporarily suppress the hyperactive stress system and alleviate the negative affective state (Wand, 2008).

**The Dopaminergic System and Reward Circuitry:**
The rewarding and reinforcing effects of drugs of abuse, including cannabis, are mediated in large part by the mesocorticolimbic dopamine system (Miyasato, 2013; Vanderschuren, 2008). While acute THC administration increases dopamine release in reward centers like the nucleus accumbens, chronic use leads to a blunting of this system. During withdrawal, the brain enters a hypodopaminergic state, characterized by reduced dopamine levels and activity within these reward circuits (Daley & Douaihy, 2019). This neurochemical deficit is believed to be a primary contributor to the anhedonia (the inability to experience pleasure), amotivation, fatigue, and intense craving experienced during withdrawal (Ramesh et al., 2011; Daley & Douaihy, 2019). The brain's reward system, now recalibrated to expect high levels of stimulation from THC, no longer responds adequately to natural rewards, contributing to a pervasive sense of dysphoria and a powerful drive to seek the drug (Daley & Douaihy, 2019).

**Noradrenergic and Serotonergic Systems:**
Dysregulation of norepinephrine (NE) and serotonin (5-HT) systems contributes significantly to the mood and arousal symptoms of withdrawal. The locus coeruleus, the brain's primary source of NE, is under inhibitory control by the ECS (Emmett et al., 2019). During withdrawal, this system becomes hyperactive, leading to a state of hyperarousal that manifests as anxiety, restlessness, irritability, and sleep disturbances like insomnia (Diferiansyah et al., 2016; Teja et al., 2020). This noradrenergic hyperactivity is a common feature across many drug withdrawal syndromes, including those from nicotine and alcohol (Hughes et al., 1994). Concurrently, alterations in the serotonin system, which is crucial for mood regulation, are implicated in the depressive symptoms, anxiety, and irritability seen in CWS (Fava & Cosci, 2019; Teja et al., 2020). The complex interplay between reduced endocannabinoid tone and dysregulated monoamine systems creates the affective instability that is a hallmark of the withdrawal experience.

**GABAergic and Glutamatergic Balance:**
A fundamental principle of CNS function is the delicate balance between inhibition, primarily mediated by gamma-aminobutyric acid (GABA), and excitation, mediated by glutamate (Söderpalm, 2002). CB1 receptors are densely located on both GABAergic and glutamatergic nerve terminals, where they act to suppress neurotransmitter release. Chronic cannabis use disrupts this balance. Upon withdrawal, the sudden removal of cannabinoid-mediated suppression leads to a state of net neuronal hyperexcitability (Becker & Redmond, 2002). This condition is analogous to the neurophysiological state observed during withdrawal from other CNS depressants like alcohol and benzodiazepines (Thompson & Weber, 2021; Pétursson, 1994; Wright, 2020). This hyperexcitability is a plausible mechanism for symptoms such as anxiety, irritability, restlessness, and insomnia (Ramesh et al., 2011). In severe cases, this excitatory/inhibitory imbalance may even lower the seizure threshold (Becker & Redmond, 2002), although seizures are a rare complication of cannabis withdrawal compared to alcohol or benzodiazepine withdrawal (Thompson & Weber, 2021).

### Brain Regions and Neural Circuits Implicated in Withdrawal

The neurochemical changes described above do not occur in a vacuum; they manifest within specific, interconnected neural circuits that govern emotion, motivation, and cognition.

**The Extended Amygdala and Stress/Anxiety Circuits:**
The extended amygdala, a macrostructure that includes the central nucleus of the amygdala and the bed nucleus of the stria terminalis, is a critical hub for processing fear, anxiety, and the negative affective components of stress and drug withdrawal (Daley & Douaihy, 2019). This region is densely populated with CB1 receptors and receives inputs from stress-mediating systems. During cannabis withdrawal, hyperactivity within the extended amygdala, driven by increased CRF and norepinephrine release and decreased endocannabinoid and GABAergic inhibition, is thought to be the central generator of the heightened anxiety, irritability, and dysphoria that characterize the syndrome (Emmett et al., 2019; Wand, 2008).

**The Prefrontal Cortex and Executive Control:**
The prefrontal cortex (PFC) is the seat of executive functions, including attention, concentration, decision-making, and impulse control (Sandi, 2013). The PFC is heavily modulated by dopamine and is also rich in CB1 receptors (Dervaux, 2013). During withdrawal, the combination of a hypodopaminergic state and disrupted endocannabinoid signaling leads to PFC dysfunction. This manifests clinically as the commonly reported withdrawal symptoms of difficulty concentrating, impaired memory, and poor decision-making (Ramesh et al., 2011; Connor et al., 2021). This impairment of "top-down" cognitive control from the PFC may also disinhibit limbic-driven craving and emotional reactivity, thereby increasing the risk of relapse (Taylor & Beckmann, 2021).

**The Hippocampus:**
The hippocampus, a region critical for memory formation and regulation of the HPA axis, has one of the highest densities of CB1 receptors in the brain (Dervaux, 2013). Disruption of hippocampal function during withdrawal likely contributes to the memory and concentration problems reported by individuals (Ramesh et al., 2011). Furthermore, altered hippocampal signaling may contribute to the dysregulation of the HPA axis, feeding into the cycle of stress and anxiety (Pérez, 2016).

**The Striatum and Basal Ganglia:**
These regions, including the nucleus accumbens, are central to reward processing, motivation, and the formation of habits (Dervaux, 2013). The withdrawal-induced hypodopaminergic state within the ventral striatum is a key driver of anhedonia, amotivation, and craving (Daley & Douaihy, 2019). Alterations in the dorsal striatum, a region more involved in habitual behaviors, may contribute to the compulsive drug-seeking that can emerge as a response to withdrawal cues (Vanderschuren, 2008).

In summary, the neurobiology of cannabis withdrawal is a multi-system phenomenon. It begins with a state of endocannabinoid deficiency that cascades into a widespread dysregulation of stress, reward, and arousal systems. This complex interplay of neurochemical imbalances across an interconnected network of brain regions gives rise to the diverse and distressing clinical syndrome that motivates many users to relapse and presents a significant challenge to achieving sustained abstinence.

## Genetic and Molecular Basis

The experience of cannabis withdrawal is notably heterogeneous; while some individuals cease use with minimal discomfort, others endure a severe and protracted syndrome that significantly impedes their attempts at abstinence (Connor et al., 2021). This variability is not random but is shaped by a complex interplay of genetic predispositions and the molecular adaptations that occur in the brain in response to chronic cannabis exposure. Understanding these factors is crucial for identifying individuals at higher risk for a difficult withdrawal and for developing personalized treatment strategies.

### Heritability and Genetic Predisposition

Substance use disorders (SUDs), including Cannabis Use Disorder (CUD), are recognized as heritable conditions (Winters & Ingwalson, 2022). Family, twin, and adoption studies have consistently shown that genetic factors contribute significantly to the risk of developing a SUD, with heritability estimates for alcohol dependence, for example, suggesting a substantial genetic variance (DiMartini, 2007). While specific heritability estimates for CWS are less established, it is highly plausible that the same genetic vulnerabilities influencing the development of CUD also modulate the severity of the withdrawal syndrome upon cessation (Koo, 2018).

This genetic predisposition likely involves a multitude of genes that regulate the function of the neurobiological systems implicated in withdrawal. For instance, variations in genes encoding components of the endocannabinoid system, such as the CB1 receptor (CNR1) or the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH), could influence an individual's baseline endocannabinoid tone and their adaptive response to chronic THC exposure. Similarly, polymorphisms in genes related to dopamine, serotonin, norepinephrine, CRF, and GABA/glutamate signaling could determine the degree to which these systems become dysregulated during withdrawal, thereby influencing the severity of specific symptom clusters like anhedonia, anxiety, or insomnia (Winters & Ingwalson, 2022; Koo, 2018). While the current body of literature does not permit the identification of specific candidate genes from the provided sources, the principle that genetic factors contribute to the risk of depression and other psychiatric disorders with overlapping symptoms provides a strong theoretical basis for their role in the individual experience of CWS (Koo, 2018).

### Molecular Mechanisms of Neuroadaptation

At the molecular level, the brain's response to chronic THC exposure involves a cascade of changes aimed at restoring synaptic homeostasis. These adaptations are the very foundation of physical dependence and are unmasked during withdrawal (Ramesh et al., 2011).

**CB1 Receptor Downregulation and Internalization:** As previously discussed, the most fundamental molecular adaptation is the reduction in the number and sensitivity of CB1 receptors (Ramesh et al., 2011). This process involves not only a decrease in the synthesis of new receptors but also the internalization of existing receptors from the cell surface, rendering them unavailable for signaling. This reduction in functional CB1 receptors means that when THC is withdrawn, endogenous cannabinoids are unable to elicit their normal physiological effects, leading to a state of widespread endocannabinoid deficiency.

**Alterations in Signal Transduction Pathways:** CB1 receptors are coupled to inhibitory G-proteins. Their activation typically leads to the inhibition of the enzyme adenylyl cyclase, which in turn reduces the intracellular concentration of the second messenger cyclic AMP (cAMP) (Hertz et al., 2014). Chronic overstimulation by THC leads to a compensatory upregulation of the cAMP pathway. During withdrawal, the removal of THC's inhibitory influence, combined with the upregulated state of the cAMP pathway, results in a dramatic "overshoot" of cAMP production. This cAMP rebound is a key molecular signature of withdrawal from many drugs that act on inhibitory G-protein coupled receptors, and it is thought to drive neuronal hyperexcitability in brain regions like the locus coeruleus and extended amygdala, contributing to the somatic and affective symptoms of withdrawal (Ramesh et al., 2011).

**Neuroplasticity and Altered Gene Expression:** The transition from controlled cannabis use to dependence and the emergence of a withdrawal syndrome involves long-term changes in neural circuitry, a process known as neuroplasticity. Chronic drug exposure and withdrawal can alter gene expression, leading to lasting changes in the synthesis of proteins crucial for synaptic structure and function, such as receptors, transporters, and signaling molecules (DiMartini, 2007). These changes can strengthen synaptic connections in pathways that promote drug-seeking (e.g., cue-induced craving) and weaken connections in circuits that mediate executive control and decision-making (e.g., PFC). For example, the repeated stress of withdrawal itself, mediated by glucocorticoids and CRF, can induce plastic changes in the hippocampus, amygdala, and PFC that contribute to heightened anxiety and cognitive deficits that persist long after acute withdrawal has subsided (Wand, 2008). These molecular and cellular adaptations represent the "scars" of chronic drug use, creating a state of vulnerability to relapse that endures for months or even years (DiMartini, 2007).

In conclusion, the biological basis of cannabis withdrawal extends to the molecular and genetic level. An individual's genetic makeup can create a predisposition for a more severe withdrawal experience, likely by influencing the function of the ECS and related neurotransmitter systems. Chronic THC exposure then drives a series of molecular adaptations, most notably CB1 receptor downregulation and altered intracellular signaling, which establish a state of physical dependence. The unmasking of these adaptations upon cessation of use is the molecular trigger for the withdrawal syndrome.

## Brain Structure and Function

The subjective experience of cannabis withdrawal—the anxiety, irritability, insomnia, and craving—is the behavioral output of objective changes in brain function and, potentially, structure. While the provided literature base is limited in primary neuroimaging studies of CWS, we can infer the functional and structural correlates by integrating knowledge of the brain regions involved in the component symptoms of withdrawal and the known effects of chronic cannabis use on brain morphology.

### Neuroimaging Findings

Neuroimaging provides a powerful window into the living brain, allowing researchers to investigate both its structure (e.g., via magnetic resonance imaging, MRI) and its function (e.g., via functional MRI, fMRI).

**Structural Findings:**
Studies on chronic cannabis users have identified subtle but significant structural alterations in several brain regions that are critical for emotion regulation, memory, and reward processing. For instance, long-term, heavy cannabis consumption has been associated with volume reductions in the hippocampus and amygdala (Dervaux, 2013). The hippocampus is integral to memory and HPA axis regulation, while the amygdala is a central hub for processing fear and anxiety (Emmett et al., 2019). Structural deficits in these areas, potentially resulting from the neurotoxic effects of chronic high-dose THC exposure or the excitotoxic stress of repeated withdrawals, could create a neuroanatomical vulnerability. This vulnerability might manifest as more severe cognitive and affective symptoms during subsequent withdrawal periods. An individual with a smaller or less resilient hippocampus, for example, may be less able to regulate the HPA axis hyperactivity that occurs during withdrawal, leading to more pronounced stress and anxiety (Pérez, 2016). These structural changes, therefore, may not be a direct result of the acute withdrawal state itself, but rather a pre-existing or drug-induced trait that modulates the severity of the withdrawal experience.

**Functional Findings:**
While direct fMRI studies of CWS are sparse in the provided literature, the well-documented symptom profile allows for strong hypotheses about the underlying functional brain states. The intense anxiety, restlessness, and irritability of withdrawal strongly suggest hyperactivity in limbic and paralimbic circuits, particularly the amygdala (Daley & Douaihy, 2019; Emmett et al., 2019). This hyperactivity would be consistent with the disinhibition of the stress circuitry following the removal of tonic CB1 receptor stimulation.

Conversely, symptoms such as anhedonia, amotivation, poor concentration, and impaired impulse control point toward hypoactivity in prefrontal and striatal circuits. The anhedonia and craving are likely linked to reduced signaling in the ventral striatum (nucleus accumbens), reflecting the hypodopaminergic state of withdrawal (Daley & Douaihy, 2019). The cognitive deficits—difficulty concentrating, indecisiveness, and memory impairment—are classic signs of PFC dysfunction (Sandi, 2013; Taylor & Beckmann, 2021). Thus, a functional neuroimaging study of an individual undergoing cannabis withdrawal would be expected to reveal a pattern of limbic hyperactivity and prefrontal hypoactivity. This "bottom-up" dominance of emotional brain regions over "top-down" cognitive control centers is a common neurobiological feature of addictive states and is a key mechanism underlying the impaired decision-making and high relapse rates associated with withdrawal (Taylor & Beckmann, 2021).

### Neural Circuits and Functional Connectivity

Modern neuroscience increasingly views brain function not in terms of isolated regions, but as the product of communication within and between large-scale neural networks. The withdrawal state can be conceptualized as a disruption of the functional connectivity—the temporal correlation of activity—within and between these critical networks.

**Cortico-Striatal Circuits:** These circuits, linking the PFC with the striatum, are essential for reward valuation, motivation, and habit formation. During withdrawal, altered connectivity in these loops likely contributes to the over-valuing of drug-related cues and the under-valuing of natural rewards, driving craving and anhedonia (Vanderschuren, 2008).

**Cortico-Limbic Circuits:** Connectivity between the PFC and limbic structures like the amygdala is fundamental for emotion regulation. In a healthy state, the PFC exerts top-down inhibitory control over amygdala activity, dampening fear and anxiety responses. During withdrawal, this connectivity is likely weakened, contributing to the uncontrolled anxiety, irritability, and emotional lability that define the syndrome (Emmett et al., 2019). The subjective feeling of being overwhelmed by negative emotions reflects this breakdown in cortico-limbic communication.

**Default Mode Network (DMN) and Executive Control Network (ECN):** The DMN is a network of brain regions active during rest and self-referential thought, while the ECN is engaged during cognitively demanding tasks. In healthy individuals, these networks are typically anti-correlated. In addiction and withdrawal, connectivity within and between these networks is often disrupted. The intrusive thoughts, craving, and difficulty concentrating during withdrawal may reflect an inability to properly deactivate the DMN and engage the ECN, leading to a state of cognitive inefficiency and preoccupation with internal distress (Sandi, 2013).

In summary, the clinical symptoms of cannabis withdrawal are manifestations of a brain in a state of functional disarray. While structural changes from chronic use may create a vulnerable landscape, the acute withdrawal syndrome is primarily a functional disorder characterized by a shift in brain activity and connectivity. This shift favors hyperactive emotional and stress circuits and hypoactive cognitive control and reward circuits, creating a neurobiological state that is highly aversive and conducive to relapse.

## Developmental Neurobiology

The impact of cannabis on the brain is not uniform across the lifespan. The developing brain is uniquely sensitive to the effects of exogenous cannabinoids, and the initiation of cannabis use during critical neurodevelopmental periods, particularly adolescence, can have profound and lasting consequences (Taylor & Beckmann, 2021). This heightened vulnerability influences not only the risk of developing CUD but also the nature and severity of the withdrawal syndrome.

### Adolescence as a Critical Period of Vulnerability

Adolescence is a period of dramatic brain maturation, characterized by extensive synaptic pruning, myelination, and refinement of neural circuits, especially within the PFC and the limbic system (Winters & Ingwalson, 2022). Crucially, the endocannabinoid system also undergoes significant developmental changes during this time, playing a key role in guiding these maturational processes (Taylor & Beckmann, 2021). The introduction of high concentrations of THC during this vulnerable window can disrupt the normal trajectory of brain development (Ashton, 2018).

Early and heavy cannabis use during adolescence is a well-established risk factor for a host of negative outcomes, including impaired educational achievement, cognitive deficits, and an increased likelihood of progressing to other illicit drug use (Hall, 2012; Catheline, 2005). From a neurobiological perspective, this vulnerability stems from the interference of THC with the ECS's role in synaptic plasticity and circuit formation (Taylor & Beckmann, 2021). Chronic THC exposure can alter the course of PFC development, leading to long-term deficits in executive function and impulse control that may persist even after cessation of use (Ashton, 2018).

This disruption of neurodevelopment has direct implications for cannabis withdrawal. Because the adolescent brain adapts more readily to the presence of THC, the neuroadaptive changes that underlie physical dependence—such as CB1 receptor downregulation—may occur more rapidly and to a greater extent (Winters & Ingwalson, 2022). Consequently, when an adolescent who uses cannabis heavily attempts to quit, they may face a more severe and protracted withdrawal syndrome compared to an adult with a similar history of use. The symptoms of withdrawal, such as irritability, anxiety, and sleep disturbance, can be particularly disruptive for an adolescent, interfering with school performance, family relationships, and social functioning (Catheline, 2005). This can create a vicious cycle, where withdrawal-related distress leads to relapse, further disrupting development and entrenching the pattern of dependence (Winters & Ingwalson, 2022).

Furthermore, the immature PFC of an adolescent is less equipped to exert top-down control over the intense cravings and negative emotions generated by the hyperactive limbic system during withdrawal (Taylor & Beckmann, 2021). This neurodevelopmental imbalance makes adolescents particularly susceptible to impulsive relapse as a means of escaping the aversive withdrawal state. Therefore, understanding the unique neurobiology of the adolescent brain is essential for designing age-appropriate prevention and treatment strategies for CUD and its associated withdrawal syndrome.

## Treatment Mechanisms

The management of cannabis withdrawal is aimed at alleviating symptoms, preventing relapse, and supporting the individual's transition to sustained abstinence (Connor et al., 2021). Treatment approaches can be broadly categorized as pharmacological and psychosocial, each targeting different aspects of the underlying neurobiology of withdrawal. While there are currently no medications specifically approved by the FDA for CWS, a number of strategies are employed based on their mechanisms of action and their efficacy in treating specific withdrawal symptoms (Thompson & Weber, 2021).

### Pharmacological Interventions and Their Biological Rationale

Pharmacological treatments for CWS are primarily directed at either stabilizing the dysregulated neurochemical systems or managing specific, distressing symptoms.

**Cannabinoid Agonist Substitution:**
A primary strategy in managing withdrawal from many substances of abuse is substitution therapy, which involves replacing a short-acting, high-potency drug with a longer-acting, lower-potency agonist to taper the patient off more comfortably. In the context of CWS, this approach involves using oral cannabinoid agonists, such as dronabinol (synthetic THC) (Ramesh et al., 2011). The biological rationale is to provide a low, steady level of CB1 receptor stimulation, thereby mitigating the severe endocannabinoid deficiency that drives withdrawal (Connor et al., 2021). This approach aims to reduce the intensity of withdrawal symptoms, allowing the brain's ECS to gradually upregulate and re-sensitize its CB1 receptors in a more controlled manner. While used "off-label" in some clinical settings, this approach requires further research to establish its efficacy and optimal protocols (Connor et al., 2021).

**Symptom-Targeted Medications:**
Given the diverse symptom profile of CWS, clinicians often prescribe medications to target specific complaints (Connor et al., 2021).
*   **Anxiolytics:** For the management of anxiety, irritability, and restlessness, benzodiazepines may be used on a short-term basis (Pétursson, 1994). These drugs enhance the effect of the inhibitory neurotransmitter GABA at the GABA-A receptor, thereby counteracting the state of neuronal hyperexcitability that characterizes withdrawal (Wright, 2020). However, their use must be cautious and time-limited due to their own potential for dependence and abuse (Pétursson, 1994; Hollister, 1977).
*   **Hypnotics:** Sleep disturbances, particularly insomnia, are among the most common and persistent withdrawal symptoms (Ramesh et al., 2011). Non-benzodiazepine hypnotics ("Z-drugs") may be used to improve sleep onset and maintenance (Connor et al., 2021). These agents also act on the GABA-A receptor system but are believed to have a more favorable side-effect profile for short-term use compared to traditional benzodiazepines (Pagel et al., 2018).
*   **Antidepressants:** For individuals with significant depressive symptoms during withdrawal, or for those with a comorbid depressive disorder, antidepressants such as Selective Serotonin Reuptake Inhibitors (SSRIs) may be considered (Connor et al., 2021). These drugs work by increasing the synaptic availability of serotonin, which can help to correct the monoaminergic dysregulation contributing to negative affect (Fava & Cosci, 2019; Montgomery et al., 1993). Their onset of action is delayed, making them less useful for acute withdrawal symptoms but potentially valuable for managing a protracted affective syndrome (Fava & Cosci, 2019).

### Psychosocial Interventions and Their Neurobiological Impact

Psychosocial treatments are the cornerstone of managing CUD and are crucial for helping individuals navigate the withdrawal period and prevent relapse. These therapies work by targeting the cognitive and behavioral patterns that sustain addiction, thereby strengthening the neurobiological substrates of self-control.

*   **Cognitive Behavioral Therapy (CBT):** CBT is one of the most effective therapies for CUD (Taylor & Beckmann, 2021). It helps individuals identify and challenge maladaptive thoughts related to cannabis use, withdrawal, and craving. It also teaches practical coping skills to manage triggers and negative emotions without resorting to substance use. From a neurobiological perspective, CBT can be conceptualized as a method for strengthening PFC-mediated "top-down" regulation of limbic-driven impulses and emotional responses (Narindra & Musabiq, 2019). By developing new cognitive strategies and behavioral responses, patients can enhance their capacity for executive control, making them more resilient to the challenges of withdrawal and craving.
*   **Motivational Enhancement Therapy (MET):** MET is a client-centered approach that aims to resolve ambivalence and enhance intrinsic motivation to change (Taylor & Beckmann, 2021). This therapy targets the brain's motivation and reward circuits. By helping individuals align their behavior with their personal values and goals, MET can help shift the balance away from the powerful reinforcement of drug use and toward the pursuit of healthy, natural rewards, thereby helping to counteract the anhedonia of withdrawal.
*   **Contingency Management (CM):** CM utilizes principles of operant conditioning by providing tangible rewards (e.g., vouchers) for objective evidence of abstinence, such as negative urine toxicology screens (Graddy & Rastegar, 2020). This approach directly engages the reward system by providing an immediate, alternative source of positive reinforcement, which can be particularly effective in counteracting the hypodopaminergic state of early withdrawal and helping to shape new, non-drug-using behaviors.

In practice, an integrated approach combining pharmacological support for acute symptoms with robust psychosocial therapy to build long-term coping skills offers the most comprehensive strategy for managing cannabis withdrawal and promoting sustained recovery (Taylor & Beckmann, 2021).

## Biological Subtypes and Heterogeneity

The clinical presentation of cannabis withdrawal syndrome is far from uniform. The severity, duration, and specific constellation of symptoms can vary dramatically from one individual to another (Connor et al., 2021). This heterogeneity reflects the complex interplay of an individual's unique biology, their specific pattern of cannabis use, and the presence of comorbid conditions. Recognizing these sources of variability is essential for a nuanced clinical understanding and for tailoring treatment to the individual.

### Symptom Clusters and Neurobiological Variability

Individuals undergoing withdrawal can present with different predominant symptom clusters. Some may experience primarily affective symptoms, such as severe anxiety, irritability, and depression (Ramesh et al., 2011). Others might be more troubled by somatic symptoms, including insomnia, decreased appetite, headaches, and sweating (Connor et al., 2021; Thompson & Weber, 2021). This variation likely reflects individual differences in the underlying neurobiological systems that are most vulnerable to dysregulation. For example, an individual with a pre-existing hyper-reactivity in their HPA axis or noradrenergic systems may be more prone to experiencing severe anxiety and restlessness during withdrawal (Wand, 2008). In contrast, someone with greater vulnerability in their dopaminergic reward pathways might suffer more intensely from anhedonia and amotivation (Daley & Douaihy, 2019). These distinct profiles suggest the existence of different biological subtypes of CWS, which could potentially predict treatment response to different pharmacological agents.

### Influence of Psychiatric and Medical Comorbidity

The presence of co-occurring psychiatric or medical disorders is a major factor contributing to the heterogeneity of CWS.
*   **Psychiatric Comorbidity:** Mood and anxiety disorders are highly comorbid with CUD (Connor et al., 2021; Ramesh et al., 2011). For an individual with a pre-existing generalized anxiety disorder or major depressive disorder, cannabis withdrawal can trigger a severe exacerbation of their underlying condition (Thompson & Weber, 2021). The symptoms of withdrawal (e.g., anxiety, insomnia, low mood) and the symptoms of the comorbid disorder become intertwined and mutually reinforcing, often leading to a more severe and complicated clinical picture (Stahl, 1993). Differentiating withdrawal from a relapse of the primary psychiatric disorder can be challenging but is critical for appropriate management (Haddad & Anderson, 2007).
*   **Polysubstance Use:** The concurrent use of other substances, particularly nicotine and alcohol, is common among regular cannabis users (Connor et al., 2021). When an individual ceases cannabis use, they may simultaneously be experiencing withdrawal from these other substances, creating a complex and overlapping withdrawal syndrome (Thompson & Weber, 2021). For example, nicotine withdrawal also involves irritability, anxiety, and difficulty concentrating (Hughes et al., 1994), while alcohol withdrawal can include anxiety, insomnia, and autonomic hyperactivity (Thompson & Weber, 2021). The interaction between these different withdrawal states can amplify the overall level of distress and complicate pharmacological management.
*   **Medical Comorbidity:** Chronic pain is another condition frequently associated with cannabis use, as many individuals use it for self-medication (Petzke et al., 2021). During withdrawal, the analgesic properties of cannabis are lost, which can lead to a rebound or worsening of underlying pain (Clendinning, 1843). This increase in pain acts as a significant additional stressor, which can exacerbate the affective symptoms of withdrawal and increase the likelihood of relapse (Hester & Tang, 2008).

### Impact of Cannabis Use Patterns

The characteristics of an individual's cannabis use are powerful determinants of withdrawal severity.
*   **Frequency and Quantity:** Daily or near-daily use of large quantities of cannabis leads to more profound neuroadaptations, such as greater CB1 receptor downregulation, and is consequently associated with a more severe withdrawal syndrome (Ramesh et al., 2011).
*   **THC Potency:** The increasing potency (THC concentration) of available cannabis products is a major public health concern (Albertson et al., 2016). Exposure to higher concentrations of THC likely accelerates the development of dependence and leads to more pronounced neuroadaptations, resulting in a more intense withdrawal experience upon cessation (Rossi & Beck, 2020).
*   **Age of Onset:** As discussed previously, initiating heavy cannabis use during adolescence disrupts neurodevelopment and is associated with a higher risk for dependence and a more severe clinical course, which likely includes a more difficult withdrawal (Taylor & Beckmann, 2021; Hall, 2012).

In essence, the clinical presentation of cannabis withdrawal is the net result of a person's neurobiological vulnerabilities interacting with the "load" placed on their system by chronic cannabis use and any co-occurring conditions. A comprehensive clinical assessment must therefore consider not just the symptoms of withdrawal, but also the individual's psychiatric history, other substance use, medical conditions, and detailed history of their cannabis consumption to fully understand and effectively manage their condition.

## Future Directions

While our understanding of the neurobiological basis of cannabis withdrawal has grown substantially, many critical questions remain unanswered. The field is poised for significant advances, driven by new technologies and a growing recognition of the public health importance of CUD. Future research should prioritize several key areas to refine our mechanistic understanding and improve clinical care.

First, there is a pressing need for more sophisticated neuroimaging studies specifically designed to investigate the CWS. Longitudinal studies that use fMRI and other techniques to track individuals from active use through cessation and into protracted abstinence are essential. Such studies could directly test hypotheses about functional connectivity changes in cortico-limbic and cortico-striatal circuits and identify the neural signatures that predict withdrawal severity and relapse risk. This would move the field from inference based on symptom profiles to direct observation of the neural dynamics of withdrawal.

Second, the genetic underpinnings of withdrawal vulnerability require much deeper exploration. Large-scale genome-wide association studies (GWAS) are needed to identify specific genetic variants that confer risk for a severe CWS. Identifying these markers could pave the way for personalized medicine, allowing clinicians to predict which patients are likely to struggle most with cessation and may benefit from more intensive pharmacological or psychosocial support from the outset (Winters & Ingwalson, 2022).

Third, the development of targeted pharmacotherapies remains a high priority. While symptomatic treatments are helpful, medications that directly address the core neurobiological dysregulations of withdrawal are needed. This could include novel agents that modulate the endocannabinoid system more subtly than direct agonists (e.g., FAAH inhibitors that increase endogenous anandamide levels) or compounds that target downstream systems like the CRF or norepinephrine pathways to specifically blunt the stress and hyperarousal components of withdrawal (Wand, 2008). Clinical trials for such agents are urgently required.

Fourth, the neurobiological consequences of withdrawal in adolescents must become a major focus of research. Given the unique vulnerability of the developing brain, it is crucial to understand how withdrawal impacts adolescent neurodevelopment and whether it confers long-term risks for psychiatric disorders (Taylor & Beckmann, 2021). This research is vital for developing age-specific treatment and prevention strategies.

Fifth, further investigation into the interactions between CWS and comorbid conditions is necessary. Research is needed to disentangle the overlapping symptom profiles of withdrawal and psychiatric disorders like depression and anxiety, and to determine how withdrawal impacts the course and treatment of these conditions (Connor et al., 2021). Understanding the combined neurobiology of CWS and polysubstance withdrawal (e.g., with nicotine) is also a critical area for future study (Hughes et al., 1994).

Finally, the development and validation of better preclinical models of cannabis withdrawal are needed to facilitate the discovery of novel treatment mechanisms. These models must accurately reflect the chronicity of use and the full spectrum of affective and somatic symptoms observed in humans to be effective platforms for screening new therapeutic compounds (Ramesh et al., 2011).

By pursuing these avenues of research, the scientific community can build upon the current foundation of knowledge to develop a more comprehensive and actionable understanding of the biological basis of cannabis withdrawal, ultimately leading to more effective interventions that can help individuals achieve and maintain abstinence.

## Conclusion

Cannabis Withdrawal Syndrome is a legitimate and clinically significant condition, rooted in demonstrable neurobiological changes that occur in response to chronic, heavy cannabis use. Its diverse symptomatology, spanning affective, somatic, and cognitive domains, is not merely a psychological reaction but a direct manifestation of a brain struggling to recalibrate its homeostatic mechanisms in the absence of exogenous cannabinoids.

The core of the syndrome lies in the profound neuroadaptation of the endocannabinoid system, primarily through the downregulation of CB1 receptors. This state of endocannabinoid hypofunction triggers a cascade of dysregulation across multiple, interconnected neurotransmitter systems. Hyperactivity in central stress and noradrenergic pathways drives the anxiety, irritability, and hyperarousal of withdrawal. A concurrent hypofunctional state in mesolimbic dopamine circuits contributes to the anhedonia, amotivation, and craving that make sustained abstinence so challenging. This complex neurochemical imbalance, occurring across a network of key brain regions including the amygdala, prefrontal cortex, and striatum, creates a state of neuronal hyperexcitability and negative affect that defines the withdrawal experience.

The severity and character of CWS are highly heterogeneous, influenced by a confluence of factors including genetic predisposition, patterns of cannabis use (especially during the vulnerable period of adolescence), and the presence of comorbid psychiatric and medical conditions. This individual variability underscores the need for a personalized approach to treatment, one that is informed by a deep understanding of the patient's unique biological and psychosocial context.

While current treatments offer support, there is a clear and urgent need for more effective, biologically-targeted interventions. Future progress hinges on continued research into the precise genetic, molecular, and circuit-level mechanisms of withdrawal. Elucidating these pathways will not only demystify the experience of those struggling to quit cannabis but will also pave the way for novel pharmacotherapies and refined psychosocial strategies. Ultimately, a comprehensive understanding of the biology of cannabis withdrawal is indispensable for reducing its burden, preventing relapse, and promoting long-term recovery for the millions of individuals affected by Cannabis Use Disorder.

## References

1. AbdulRahman, I., Yaqoob, Ú., & Bhatti, T. A. (2018). Sleep Disorders Caused by Depression. Clinical Depression. https://doi.org/10.4172/2572-0791.1000131
2. Abi‐Jaoude, E., Stall, N. M., & Rochon, P. A. (2018). Psychotropic drugs for the behavioural and psychological symptoms of dementia: no free ride. Canadian Medical Association Journal. https://doi.org/10.1503/cmaj.181486
3. Ahemad, M., Ahmad, P. M. F., & Shafaat, M. (2018). Effect of Dalak (Massage) in the Management of Sahar (Insomnia). https://doi.org/10.37591/rrjoush.v5i2.130
4. Albertson, T. E., Chenoweth, J., Colby, D., & Sutter, M. E. (2016). The Changing Drug Culture: Medical and Recreational Marijuana.. PubMed.
5. Alexandre, S., Misery, L., Dutray, S., Chastaing, M., Consoli, S.-M., Audra, H., Bauer, D., Bertolus, S., Callot, V., Cardinaud, F., Corrin, E., Féton-Danou, N., Malet, R., Touboul, S., & Consoli, S. (2007). Functional Itch Disorder or Psychogenic Pruritus: Suggested Diagnosis Criteria From the French Psychodermatology Group. Acta Dermato Venereologica. https://doi.org/10.2340/00015555-0266
6. Ali, A. M., Al‐Dossary, S. A., Laranjeira, C., Atout, M., Khatatbeh, H., Selim, A., Alkhamees, A. A., Aljaberi, M. A., Pakai, A., & Al‐Dwaikat, T. (2024). Cardiometabolic Morbidity (Obesity and Hypertension) in PTSD: A Preliminary Investigation of the Validity of Two Structures of the Impact of Event Scale-Revised. Journal of Clinical Medicine. https://doi.org/10.3390/jcm13206045
7. Ali, M., Malathesh, B. C., Chatterjee, S. S., Das, S., & Prasad, S. (2022). Mania/Hypomania induced by quetiapine: A case report and review of literature. Psychiatry Research Case Reports. https://doi.org/10.1016/j.psycr.2022.100093
8. Ali, N., Rasheed, A., Tariq, I., Abdullah, F., Sarwar, A., Atta, R., & Qammer, Z. (2018). Adjunct Use of Low Dose Risperidone Verses Adjunct Use of Clonazepam with an SSRI in Treatment of Moderate to Severe Anxiety States; A Comparative Study. National Journal of Health Sciences. https://doi.org/10.21089/njhs.32.0051
9. Allgulander, C., & Baldwin, D. S. (2013). Pharmacotherapy of Generalized Anxiety Disorder. Modern trends in psychiatry. https://doi.org/10.1159/000351955
10. Amoah, C., Heck, D. E., & Kim, H. D. (2022). Sensing metabolomics landscape unfold molecular connectivity between mental illness and drug abuse. GSC Biological and Pharmaceutical Sciences. https://doi.org/10.30574/gscbps.2022.18.3.0102
11. Amorim, M. J., Maurício, J., & Brandão, D. (2019). WHEN THE DISEASE ARISES FROM THE TREATMENT: CORTICOSTEROID-INDUCED PSYCHOSIS A CASE REPORT AND BRIEF LITERATURE REVIEW. https://doi.org/10.26226/morressier.5d1a037b57558b317a140b63
12. Ananto, A. S., & Suryati, E. (2019). Ensefalopati Hipertensi pada Anak dengan Glomerulonefritis Akut Pasca Streptokokal.
13. Andrade, C. (2022). Psychotropic Drugs With Long Half-Lives. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.22f14593
14. Andrasik, F., Lipchik, G. L., McCrory, D. C., & Wittrock, D. A. (2005). Outcome Measurement in Behavioral Headache Research: Headache Parameters and Psychosocial Outcomes. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2005.05094.x
15. Anghelescu, A., Magdoiu, A. M., Chirilă, I., Verișezan, O., Opincariu, I., Mureșanu, D. F., & Blesneag, A. (2018). None. Romanian Journal of Neurology. https://doi.org/10.37897/rjn.2018.s
16. Anghelescu, G., Bojescu, A. A., Populeanu, R., Ionică, M., Vlădescu, M., Macovei, R. A., & Caragea, G. (2018). Multiple reactions monitoring for cocaine and ethylbenzoylecgonine to increase the signal/noise ratio in mass spectrometry analysis. Advanced Topics in Optoelectronics, Microelectronics, and Nanotechnologies IX. https://doi.org/10.1117/12.2322569
17. Anisman, H., & Merali, Z. (2003). Cytokines, stress and depressive illness: brain‐immune interactions. Annals of Medicine. https://doi.org/10.1080/07853890310004075
18. Ansari, A., Jain, A., Mittal, R., Sharma, A., Sharma, A., & Gupta, I. (2016). Role of Sertraline in insomnia associated with post traumatic brain injury (TBI) depression. Romanian Neurosurgery. https://doi.org/10.1515/romneu-2016-0068
19. Araya, E. I., Gambeta, E., Lejeune, V. B. P., Turnes, J. M., Jesus, C. H. A., & Chichorro, J. G. (2022). Chronic Pain: Focus on Anticonvulsants. Frontiers in clinical drug research. CNS and neurological disorders. https://doi.org/10.2174/9789815040678122100008
20. Argyriou, A. A., Anastopoulou, G. G., & Bruna, J. (2018). Inconclusive evidence to support the use of minimally-invasive radiofrequency denervation against chronic low back pain. Annals of Translational Medicine. https://doi.org/10.21037/atm.2018.01.23
21. Arredondo-Aldana, K., Mera-Posligua, M. J., & Alencastro, J. A. P. (2021). Trastorno Depresivo Persistente y Trastornos de Ansiedad Generalizada Proveniente de un Estrés Post Traumático Crónico: Presentación de un Caso Clínico. Revista Científica Arbitrada en Investigaciones de la Salud GESTAR. https://doi.org/10.46296/gt.v4i8edesp.0027
22. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2013). Nonconvulsive status epilepticus and psychotic symptoms: case report.. PubMed. https://doi.org/10.1708/1292.14295
23. Arteaga, T. L., Amo, C., González, C. S., & Sánchez, D. H. (2016). Nonconvulsive status epilepticus and psychotic symptoms: case report Stato epilettico non convulsivo e sintomi psicotici: caso clinico.
24. Ashton, H. (1994). The treatment of benzodiazepine dependence. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03755.x
25. Ashton, J. C. (2018). Is Cannabis Harmless? Focus on Brain Function. Current Drug Research Reviews. https://doi.org/10.2174/2589977511666180809165622
26. Athanasou, J. A. (2016). Substance Abuse. SensePublishers eBooks. https://doi.org/10.1007/978-94-6300-657-6_17
27. Autor, S. (2002). CÁPSULAS PARA LA VIDA.- ANSIEDAD. Gaceta UNAM (2000-2009).
28. Ayoob, A., & Janakiram, C. (2021). Let's Focus on Frailty. Journal of Indian Association of Public Health Dentistry. https://doi.org/10.4103/jiaphd.jiaphd_93_21
29. B.R, R., & N.K.C, E. (2019). A review on pain and its signals modulation by body. IP International Journal of Comprehensive and Advanced Pharmacology. https://doi.org/10.18231/j.ijcaap.2019.018
30. Baldwin, D. S., & Ajel, K. (2007). Role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Disease and Treatment. https://doi.org/10.2147/nedt.2007.3.2.185
31. Barré, M. (2013). Influence de la cognition sociale (Théorie de l'Esprit) sur la rémission fonctionnelle de la dépression et l'aptitude professionnelle.
32. Bartels, K., & Schacht, J. P. (2021). Cocaine-Positive Patients Undergoing Elective Surgery: From Avoiding Case Cancellations to Treating Substance Use Disorders. Anesthesia & Analgesia. https://doi.org/10.1213/ane.0000000000004969
33. Baum, R., & Campo, J. V. (2022). Medically Unexplained Symptoms. Pediatric Care Online. https://doi.org/10.1542/aap.ppcqr.396501
34. Baumann, P., & Martin-Du, P. R. (2008). Sexual dysfunctions induced by antidepressants and antipsychotics.
35. Bausewein, C., & Schildmann, E. (2022). Symptomkontrolle am Lebensende. Therapeutische Umschau. https://doi.org/10.1024/0040-5930/a001327
36. Becker, H. C., & Redmond, N. (2002). Role of Glutamate in Alcohol Withdrawal Kindling. Humana Press eBooks. https://doi.org/10.1007/978-1-59259-306-4_25
37. Belmaker, R. H. (2007). Treatment of Bipolar Depression. New England Journal of Medicine. https://doi.org/10.1056/nejme078042
38. Berliner, D., Schneider, N., Welte, T., & Bauersachs, J. (2016). The Differential Diagnosis of Dyspnea. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2016.0834
39. Berra, K., Fletcher, B. J., & Miller, N. H. (2008). Chronic stable angina: Addressing the needs of patients through risk reduction, education and support. Clinical and investigative medicine. https://doi.org/10.25011/cim.v31i6.4927
40. Bingöl, A. (2003). Nadir bir geçici iskemik atak nedeni: nörobrusellozis. https://doi.org/10.1501/0001016
41. Bixquert, M. (2013). Treatment of irritable bowel syndrome with probiotics: growing evidence.. PubMed.
42. Bolten, M., & Légeret, C. (2021). Interface entre pédopsychiatrie et pédiatrie – illustré par le concept bâlois du traitement interdisciplinaire des troubles fonctionnels de la défécation. Paediatrica Métabolisme/maladies rares. https://doi.org/10.35190/f2021.2.1
43. Bond, C., Morgenstern, J., & Milne, W. K. (2022). Hot off the press: <scp>MRI</scp> sensitivity for transient global amnesia. Academic Emergency Medicine. https://doi.org/10.1111/acem.14540
44. Bonnet, M. H., & Arand, D. L. (2008). Chronic insomnia. CRC Press eBooks. https://doi.org/10.3109/9780203091715-12
45. Bonnet, M. H., & Arand, D. L. (2013). Insomnia. https://doi.org/10.3920/9789086867639_003
46. Boodidha, P., Tushara, B., Sireesha, M., Priya, V. S., & Priya, L. K. (2021). Sleep – A Rare Gift: A Detail Review Study on Insomnia. Scholars Academic Journal of Pharmacy. https://doi.org/10.36347/sajp.2021.v10i11.003
47. Borowski, M. (2013). Addiction as a Disease. European Researcher. https://doi.org/10.13187/er.2013.55.1945
48. Bran, C. (2021). BURNOUT VERSUS WELL-BEING IN ORGANIZATIONS. Journal Plus Education.
49. Brody, D. L. (2019). How Do You Make the Diagnosis of Concussion?. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0003
50. Brody, D. L. (2019). Mood Instability and Irritability. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190054793.003.0010
51. Broomfield, N. M., Wild, M. R., & Espie, C. A. (2008). Assessment and treatment of insomnia in later life. Oxford University Press eBooks. https://doi.org/10.1093/med:psych/9780198569459.003.0011
52. Browne, R. B. (2011). The Belle Browne Pain Scale.
53. Bryois, C. (2005). Principes de prise en charge des troubles anxieux par le médecin de premier recours. Forum Médical Suisse ‒ Swiss Medical Forum. https://doi.org/10.4414/fms.2005.05571
54. BS, A. H., & BA, M. F. (2018). Glossary. https://doi.org/10.1002/9781119449737.gloss
55. BSc, P. L. G. R., & BSc, D. B. R. (2008). Glossary of Technical Terms. https://doi.org/10.1002/9781444302264.gloss
56. Buchwald, A. M., & Rudick-Davis, D. (1993). The symptoms of major depression.. Journal of Abnormal Psychology. https://doi.org/10.1037//0021-843x.102.2.197
57. Budson, A. E., & O’Connor, M. K. (2021). How to manage emotional problems. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780190098124.003.0008
58. Bujosa, C. M., & Monsalve, M. H. (2007). Caso Clínico "La esquizofrenia de inicio senil o cuando el reto de saber pseudodiagnosticar". Norte de Salud mental.
59. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Le trouble hyperkinétique ou déficit de l'attention/hyperactivité. Le point sur... Psychologie.
60. Bénony, H., Bénony-Viodé, C., & Dumas, J. (2012). Les troubles de l'humeur. Le point sur... Psychologie.
61. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Post-Stroke Apathy: An Exploratory Longitudinal Study. Cerebrovascular Diseases. https://doi.org/10.1159/000350202
62. Caeiro, L., Ferro, J. M., Melo, T. P. E., Canhão, P., & Figueira, M. L. (2013). Supplementary Material for: Post-Stroke Apathy: An Exploratory Longitudinal Study. Figshare. https://doi.org/10.6084/m9.figshare.5124829
63. Calvani, M., Anania, C., Cuomo, B., D’Auria, E., Decimo, F., Indirli, G. C., Mastrorilli, V., Santoro, A., Sartorio, M. U. A., & Veronelli, E. (2020). Summation anaphylaxis: A challenging diagnosis. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13347
64. Canapathy, M., Kurushev, J., Chitra, F., & Dash, M. (2019). Impact of Sensory Deprivation on Health Outcome. Acta Scientific Paediatrics. https://doi.org/10.31080/aspe.2019.02.0165
65. Cano‐Vindel, A., Miguel-Tobal, J. J., González, H. M., & Díez, I. I. (1994). El afrontamiento de la ansiedad en las drogodependencias. Anales de Psicología.
66. Carlson, G. A., & Pataki, C. (2016). Disruptive Mood Dysregulation Disorder Among Children and Adolescents. FOCUS The Journal of Lifelong Learning in Psychiatry. https://doi.org/10.1176/appi.focus.20150039
67. Carvajal-Lohr, A., Flores‐Ramos, M., Montejo, S. I., & Vidal, C. G. (2016). Los trastornos de ansiedad durante la transición a la menopausia. Perinatología y Reproducción Humana. https://doi.org/10.1016/j.rprh.2016.03.003
68. Casey, P. (2018). Making the diagnosis in clinical practice (DRAFT). Oxford University Press eBooks. https://doi.org/10.1093/med/9780198786214.003.0006
69. Castello, M., Gutiérrez, A. A., Rodríguez, L. S., Pérez, I. S., Arévalo, A. J., & Sempere, E. P. (2025). Acute confusional state vs psychological and behavioral symptoms of dementia. About a case. European Psychiatry. https://doi.org/10.1192/j.eurpsy.2025.1797
70. Cates, A. N. D., & Giorgi, R. D. (2020). Adjunctive benzodiazepines in depression: a clinical dilemma with no recent answers from research. BJPsych Advances. https://doi.org/10.1192/bja.2020.17
71. Catheline, N. (2005). [Academic problems and school failure in adolescence].. PubMed.
72. Cha, Y., Baloh, R. W., Cho, C., Magnusson, M., Song, J., Strupp, M., Wuyts, F. L., & Staab, J. P. (2020). Mal de débarquement syndrome diagnostic criteria: Consensus document of the Classification Committee of the Bárány Society. Journal of Vestibular Research. https://doi.org/10.3233/ves-200714
73. Chang, Y.-S., Anderson, N., Long, K., Murphy, C., McMahan, V., Rodda, L. N., Kral, A. H., & Coffin, P. O. (2025). Refining cause of death attribution among opioid, opioid‐stimulant and stimulant acute toxicity deaths. Addiction. https://doi.org/10.1111/add.70190
74. Chaouloff, F., Dubreucq, S., Matias, I., & Marsicano, G. (2013). Physical activity feel-good effect:The role of endocannabinoids. Routledge eBooks. https://doi.org/10.4324/9780203132678-12
75. Charlton, S. R. (2020). Psychology and Black History Month in the United States. Eye on Psi Chi Magazine. https://doi.org/10.24839/2164-9812.eye24.4.18
76. Chatterton, C., & Jones, G. (2013). Interpretative aspects of toxicological results. https://doi.org/10.4155/ebo.13.54
77. Chesney, E., Reilly, T. J., Scott, F., Slimani, I., Sarma, A. V. S., Kornblum, D., Oliver, D., & McGuire, P. (2024). Psychosis associated with cannabis withdrawal: systematic review and case series. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.2024.175
78. Chuen, L. H. (2022). Traditional Chinese Medicine Offers Help to Marijuana Users Determined to Withdraw Report of Two Typical Cases. Journal of Drugs Addiction & Therapeutics. https://doi.org/10.47363/jdat/2022(3)121
79. Cienfuegos, J. J., Arriaga, M. Á. A., García, J. J., & Fernández, A. C. S. (2021). Propuesta de establecimiento de hábitos y rutinas que contemplen ejercicio y manejo del estrés para evitar el desgaste laboral durante el home office. Ciencia Latina Revista Científica Multidisciplinar. https://doi.org/10.37811/cl_rcm.v5i3.583
80. Clarkson, P. M., & Miles, M. P. (1994). Exercise-induced muscle pain, soreness, and cramps.. PubMed.
81. Clendinning, J. (1843). Observations on the Medicinal Properties of the Cannabis Sativa of India. Medico-chirurgical transactions. https://doi.org/10.1177/095952874302600116
82. Cohen, J. A., Mowchun, J. J., Lawson, V. H., & Robbins, N. M. (2016). A 19-Year-Old Male with Stiffness and Weakness After Waking. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190491901.003.0026
83. Colombo, M. A. (2018). Insomnia disorder and endogenous neurophysiological dynamics.
84. Colán, T. C., Gálvez, G. A., & Zevallos, D. C. (2013). Síntomas psiquiátricos e insulinoma: reporte de caso Psychiatric symptoms and insulinoma: a case report.
85. Connell, J., Oldham, M., Pandharipande, P. P., Dittus, R. S., Wilson, A. M., Mart, M. F., Heckers, S., Ely, E. W., & Wilson, J. E. (2022). Malignant Catatonia: A Review for the Intensivist. Journal of Intensive Care Medicine. https://doi.org/10.1177/08850666221114303
86. Connelly, M., & Weydert, J. A. (2016). Chronic Pediatric Pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199315246.003.0053
87. Connor, J. P., Stjepanović, D., Budney, A. J., Foll, B. L., & Hall, W. (2021). Clinical management of cannabis withdrawal. Addiction. https://doi.org/10.1111/add.15743
88. Corrigall, W. A. (2003). A Rodent Model for Nicotine Self-Administration. Humana Press eBooks. https://doi.org/10.1385/0-89603-217-5:315
89. Cox, R. C., Wright, K. P., Axelsson, J., & Balter, L. J. T. (2024). Diurnal variation in anxiety and activity is influenced by chronotype and probable anxiety-related disorder status. Psychiatry Research. https://doi.org/10.1016/j.psychres.2024.116006
90. Cristian, D. (2013). SOLUTIONS TO FIGHT AGAINST OVERTRAINING IN BODYBUILDING ROUTINE. Marathon.
91. Cruz, M. C. D., Camargo, R. P. D., Cruz, L. C. D., Schiefelbein, N., Cruz, D. M. D., & Cruz, M. C. C. D. (2020). Migrânea: revisão de literatura. ARCHIVES OF HEALTH INVESTIGATION. https://doi.org/10.21270/archi.v10i2.4670
92. Cunnington, D., & Junge, M. (2016). Chronic insomnia: diagnosis and non-pharmacological management. BMJ. https://doi.org/10.1136/bmj.i5819
93. Cárdenas, J. F., & McLeod, T. C. V. (2024). Are There Any Medications That May Be Useful in the Management of Concussions?. Routledge eBooks. https://doi.org/10.4324/9781003526131-31
94. Daley, D. C., & Douaihy, A. (2019). Managing Cravings and Urges to Use Substances. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926717.003.0009
95. Daley, D. C., & Douaihy, A. (2019). Substance-Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190926632.003.0002
96. Das, C., & Joseph, S. (2005). Falls in elderly.. PubMed.
97. Delgado, D. A. O., Rojas, M. C. O., & Olea, J. M. S. (2024). Episodio depresivo mayor de características catatónicas: Reporte de caso. Revista Científica de Salud y Desarrollo Humano. https://doi.org/10.61368/r.s.d.h.v5i1.75
98. Dennis, M., Warlow, C. P., Gijn, J. V., Wardlaw, J. M., Bamford, J., Hankey, G. J., Sandercock, P., Rinkel, G. J., Langhorne, P., Sudlow, C., & Rothwell, P. M. (2008). What are This Patient's Problems?: A Problem‐Based Approach to the General Management of Stroke. Stroke. https://doi.org/10.1002/9780470696361.ch11
99. Dervaux, A. (2013). En quoi et comment le cannabis peut-il être toxique pour le cerveau ?. European Psychiatry. https://doi.org/10.1016/j.eurpsy.2013.09.004
100. Devi, C. B. P., Samreen, S., Kumari, N. K., & Sharma, J. (2018). A review on insomnia: The sleep disorder. Deleted Journal.
101. Dhar, N., Shree, R., Radhakrishnan, D. M., & Kumar, N. (2020). Hearing Loss in Migraine: An Uncommon Manifestation of a Common Disorder. Journal of Neurosciences in Rural Practice. https://doi.org/10.1055/s-0040-1713337
102. Diferiansyah, O., Septa, T., & Lisiswanti, R. (2016). Gangguan Cemas Menyeluruh. Jurnal Medula.
103. DiMartini, A. (2007). Natural history of alcohol use disorders in liver transplant patients. Liver Transplantation. https://doi.org/10.1002/lt.21342
104. Ding, K., Gupta, P. K., & Diaz‐Arrastia, R. (2016). Epilepsy after Traumatic Brain Injury. CRC Press, Taylor and Francis Group eBooks.
105. Dodick, D. W., & Roarke, M. C. (2007). Familial Hemiplegic Migraine: Permanent Attack‐Related Neurologic Deficits. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2007.00889.x
106. Domínguez, M. R., Burgos, L. M., & Bergink, V. (2020). Perinatal Mood and Anxiety Disorders. Obstetrics and gynecology.. https://doi.org/10.1002/9781119450047.ch16
107. Doyle, A., & Pollack, M. H. (2003). Establishment of Remission Criteria for Anxiety Disorders. The Primary Care Companion To The Journal of Clinical Psychiatry.
108. Drogin, E. Y., Dattilio, F. M., Sadoff, R. L., & Gutheil, T. G. (2011). Appendix A: Scientific Glossary. https://doi.org/10.1002/9781118093399.app1
109. Duits, N., & Bos, F. M. (1993). [Psychiatric disorders with use of simvastatin].. PubMed.
110. Durán, L. V. B., González, M., & Álvarez, G. B. (2020). Trastorno por estrés postrauma. Revista Medica Sinergia. https://doi.org/10.31434/rms.v5i9.568
111. Délano, P. H., Holmes, A., & Díaz, C. (2022). Mal de desembarque. Revista de otorrinolaringología y cirugía de cabeza y cuello. https://doi.org/10.4067/s0718-48162022000300343
112. D’Arrigo, T. (2020). Cannabis Withdrawal Syndrome Affects Nearly Half of Those Who Quit. Psychiatric News. https://doi.org/10.1176/appi.pn.2020.6a4
113. D’cruz, M., Andrade, C., & Rao, T. S. (2020). The Expression of Intimacy and Sexuality in Persons With Dementia. Journal of Psychosexual Health. https://doi.org/10.1177/2631831820972859
114. Efeoğlu, P., Dağlıoğlu, N., Hilal, A., & Gülmen, M. K. (2013). Drugs Used in Sexual Assaults: Features and Toxicological Investigations. DergiPark (Istanbul University).
115. Eisen, J. S., Macfarlane, J., & Shapiro, C. M. (1993). ABC of sleep disorders. Psychotropic drugs and sleep.. BMJ. https://doi.org/10.1136/bmj.306.6888.1331
116. Elhassan, N. M., Al‐Salihy, Z., Bushra, M., Sanabel, A.-A., Albobaly, Y., Eltorki, Y., & Alabdulla, M. (2018). Use of Benzodiazepines and Hypnotic Medications in Psychiatry Older Adult Outpatients. International Journal of Case Reports. https://doi.org/10.28933/ijcr-2018-11-1006
117. Emmett, S. R., Hill, N. A., & Dajas‐Bailador, F. (2019). Psychiatry. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780199694938.003.0018
118. Escalante, M. L., Merejildo, W. P., Contreras, V. S., & Barroso, C. I. (2016). Cefalea hipnica secundaria a malformación arteriovenosa cerebral.
119. Escribano, S. A. (2018). Estudio de la eficacia de un tratamiento psicológico breve en la disminución de la sensibilidad a la ansiedad en pacientes con trastorno de pánico.
120. Espay, A. J., Fox, S. H., Marras, C., Lang, A. E., & Chen, R. (2007). Isolated diaphragmatic tremor. Neurology. https://doi.org/10.1212/01.wnl.0000267431.16316.69
121. Evers, M. M., & Marin, D. B. (2002). Mood disorders. Effective management of major depressive disorder in the geriatric patient.. PubMed.
122. Fachrudin, D. (2019). Episode Depresif Berat dengan Gejala Psikotik (Studi Kasus dalam Perspektif Psikologi dengan Pendekatan Teori Kognitif Beck). Tunas Medika Jurnal Kedokteran & Kesehatan.
123. Fatma, S., & Anjum, R. (2020). Insomnia disorder: A review. International journal of applied research.
124. Fava, G. A., & Cosci, F. (2019). Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.19com12794
125. Feder, H. M., & Wormser, G. P. (2021). Studying College Students for the Development of Infectious Mononucleosis and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciab075
126. Finegan, W. C., McGurk, A., O’Donnell, W., Pederson, J., & Rogerson, E. (2018). Nausea and vomiting. CRC Press eBooks. https://doi.org/10.4324/9781315378527-41
127. Finsterer, J., & Zarrouk‐Mahjoub, S. (2013). Fatigue in Healthy and Diseased Individuals. American Journal of Hospice and Palliative Medicine®. https://doi.org/10.1177/1049909113494748
128. Fischer, T., Agar, M., Hosie, A., & Teodorczuk, A. (2020). Unpacking agitation in practice: a call for greater precision. Age and Ageing. https://doi.org/10.1093/ageing/afaa110
129. Frazer, E. (2019). Post Traumatic Stress Disorder in Emergency Medical Services. CRC Press eBooks. https://doi.org/10.1201/9781315607450-20
130. Frean, J., Jong, G. D., & Albrecht, R. (2008). Imaginary bugs, real distress: delusional parasitosis.. PubMed.
131. Friedman, D. I. (2016). Your Loved One Has Migraines. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/head.12880
132. Friedman, D. I., Wall, M., & Silberstein, S. D. (2007). Headache Associated with Abnormalities in Intracranial Structure or Function: Highcerebrospinalfluid-pressure Headache and Brain Tumor. https://doi.org/10.1093/oso/9780195326567.003.0018
133. Fujita, M., & Tsuruta, R. (2013). Pathophysiology and prevention of delayed neurological sequelae in carbon monoxide poisoning. Journal of the Japanese Society of Intensive Care Medicine. https://doi.org/10.3918/jsicm.20.373
134. Galili, S. F. (2019). Følger af det milde hovedtraume. Dansk Tidsskrift for Akutmedicin. https://doi.org/10.7146/akut.v2i1.104546
135. Galima, S. V., Vogel, S. R., & Kowalski, A. W. (2020). Seasonal Affective Disorder: Common Questions and Answers..
136. Ganda, K. M. (2013). Psychiatric Conditions: Assessment of Disease States and Associated Dental Management Guidelines. https://doi.org/10.1002/9781119421450.ch52
137. Goldstein, D. S. (2020). The possible association between COVID-19 and postural tachycardia syndrome. Heart Rhythm. https://doi.org/10.1016/j.hrthm.2020.12.007
138. González, M. F. A. (2019). DETERMINACIÓN DE LOS EFECTOS FISIOLÓGICOS CAUSADOS POR ESTRÉS ACADÉMICO Y LABORAL EN ESTUDIANTES DE QUÍMICA Y QUÍMICO FARMACÉUTICO BIOLÓGO.
139. Graddy, R., & Rastegar, D. A. (2020). Stimulants. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197506172.003.0008
140. Grant, I., Sacktor, N., & McArthur, J. C. (2005). HIV neurocognitive disorders. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780198526100.003.0035
141. Gray, A. (2003). Quality use of medicines: The patient with Acute Cough. South African Family Practice. https://doi.org/10.4102/safp.v45i8.1896
142. Greydanus, D. E., Calles, J. L., & Patel, D. R. (2008). Anxiety disorders. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544705.007
143. Groisman, A. E., & Seminatore, M. L. (2003). Children and Adolescents Who Have Schizophrenia. Pediatrics in Review. https://doi.org/10.1542/pir.24.10.356
144. Gupta, S., Laddha, A., Chaturvedi, P., Chaturvedi, N., Mishra, A., & Raghvendra, R. (2011). Trends and strategy towards therapies for status epilepticus: A decisive review. International Journal of Pharmaceutical Sciences Review and Research.
145. Guskiewicz, K. M., & Goldman, S. B. (2013). A Changing Landscape: Traumatic Brain Injury in Military Combat and Civilian Athletics. The FASEB Journal. https://doi.org/10.1096/fj.13-1101ufm
146. Guthrie, T. R. (2021). Other Health Impairment (OHI) Disabilities Category and an In-Depth Look at the Most Common Neurobiological Condition for Students. Advances in higher education and professional development book series. https://doi.org/10.4018/978-1-7998-7359-4.ch003
147. Güleç, H., Babayiğit, M., Kurtay, A., Şahap, M., Ulus, F., Tutal, Z. B., & Horasanlı, E. (2014). Seizure due to multiple drugs intoxication: a case report. Brazilian Journal of Anesthesiology (English Edition). https://doi.org/10.1016/j.bjane.2014.02.013
148. Gündoğmuş, İ., Karagöz, A., & Algül, A. (2018). First-episode psychosis induced by pregabalin withdrawal: a case report. Psychiatry and Clinical Psychopharmacology. https://doi.org/10.1080/24750573.2018.1452523
149. Haddad, P., & Anderson, I. (2007). Recognising and managing antidepressant discontinuation symptoms. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.bp.105.001966
150. Hainline, B., Gurin, L., & Torres, D. M. (2019). Concussion Two Weeks Later. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190937447.003.0007
151. Hall, W. (2012). The mental health effects of cannabis use. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199696758.003.0068
152. Hao, Y., Controzzi, M., Cipriani, C., Popović, D. B., Yang, X., Chen, W., Zheng, X., & Carrozza, M. C. (2013). Controlling hand-assistive devices: utilizing electrooculography as a substitute for vision. IEEE Robotics & Automation Magazine. https://doi.org/10.1109/mra.2012.2229949
153. Hautzinger, M. (1993). Depressionen. Verhaltenstherapie. https://doi.org/10.1007/978-3-662-22591-2_63
154. Hernández, Y. D. C. S. (2016). Alteraciones estructurales de las regiones cerebrales sexuales tras empleo de paroxetina versus agomelatina. https://doi.org/10.14201/gredos.129703
155. Hertz, L., Song, D., Li, B., Du, T., Xu, J., Gu, L., Chen, Y., & Liang, P. (2014). Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. Journal of Signal Transduction. https://doi.org/10.1155/2014/593934
156. Hester, J., & Tang, N. K. Y. (2008). Insomnia Co-Occurring with Chronic Pain: Clinical Features, Interaction, Assessments and Possible Interventions. Reviews in Pain. https://doi.org/10.1177/204946370800200102
157. Hines, S. C., Maharty, D. C., & Brown, R. B. (2024). Chronic Low Back Pain in Adults: Evaluation and Management.. PubMed.
158. Hirschfeld, R. M. A., Calabrese, J. R., Frye, M. A., Lavori, P. W., Sachs, G., Thase, M. E., & Wagner, K. D. (2007). Defining the clinical course of bipolar disorder: response, remission, relapse, recurrence, and roughening.. PubMed.
159. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2024). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-024-01880-2
160. Hocker, S. E., Wijdicks, E. F. M., & Rabinstein, A. A. (2013). Refractory status epilepticus: new insights in presentation, treatment, and outcome. Neurological Research. https://doi.org/10.1179/1743132812y.0000000128
161. Holgate, S. T. (2002). Considerations on third generation antihistamines. Clinical & Experimental Allergy. https://doi.org/10.1046/j.1365-2222.2002.01339.x
162. Hollister, L. E. (1977). Withdrawal From Benzodiazepine Therapy. JAMA. https://doi.org/10.1001/jama.1977.03270410032003
163. Holmes, G. L., & Bingham, P. M. (2016). The Headache That Wouldn’t Go Away. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190601508.003.0030
164. Hong, C. (2013). 분과 심포지움 2. 임상 : 새로운 진단체계 DSM-5; 조현병 스펙트럼 및 기타 정신병적 장애,성격장애. 한국심리학회 연차 학술발표논문집.
165. Howland, R. H. (2014). Psychotropic Medication Use:What Will It Do To My Liver?. Journal of Psychosocial Nursing and Mental Health Services. https://doi.org/10.3928/02793695-20140722-01
166. Hughes, J. R., Higgins, S. T., & Bickel, W. K. (1994). Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03744.x
167. Ikeda, A. (2016). I. How to Make a Diagnosis of Epilepsy and Its Classification. Nihon Naika Gakkai Zasshi. https://doi.org/10.2169/naika.105.1348
168. Inmaculada, M., & Pérez, P. B. (2016). Neuronal and behavioural effects of social isolation in old age.
169. Irom, B. S. (2020). Is Mental Health Condition a Cause of Anxiety. Journal of Traumatic Stress Disorders & Treatment. https://doi.org/10.37532/2324-8947.2020.9(6).217
170. Itani, R., Soubra, L., Karout, S., Rahme, D., Karout, L., & Khojah, H. M. J. (2022). Primary Dysmenorrhea: Pathophysiology, Diagnosis, and Treatment Updates. Korean Journal of Family Medicine. https://doi.org/10.4082/kjfm.21.0103
171. Jiménez, D. E. A. (2020). El trastorno por consumo de alcohol como producto del conflicto intrapsíquico. Revista Torreón Universitario. https://doi.org/10.5377/torreon.v9i26.10261
172. Kailin, M., Fernández, V., Peng, C., & Black, C. (2024). Anxiety and Trauma‐related Disorders due to the COVID‐19 Pandemic. https://doi.org/10.1002/9781394250103.ch6
173. Kaplan, H., Sadock, B. J., & Grebb, J. A. (1994). Kaplan and Sadock's synopsis of psychiatry : behavorial sciences, clinical psychiatry. Williams & Wilkins eBooks.
174. Karila, L., Roux, P., Rolland, B., Benyamina, A., Reynaud, M., Aubin, H., & Lançon, C. (2014). Acute and Long-Term Effects of Cannabis Use: A Review. Current Pharmaceutical Design. https://doi.org/10.2174/13816128113199990620
175. Kazymova, N., Kharlamenkova, N. Y., & Nikitina, D. A. (2019). Severe life events and their psychological consequences: loss or threat of loss of nearest. Vestnik Kostroma State University Series Pedagogy Psychology Sociokinetics. https://doi.org/10.34216/2073-1426-2019-25-2-96-101
176. Keary, C. J., Nejad, S. H., Rasimas, J. J., & Stern, T. A. (2013). Intoxications Associated With Agitation, Tachycardia, Hypertension, and Fever: Differential Diagnosis, Evaluation, and Management. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.12f01459
177. Kellett, J. M. (1993). Long term care on the NHS: a vanishing prospect.. BMJ. https://doi.org/10.1136/bmj.306.6881.846
178. Kennedy, J. E., Jaffee, M. S., & Cooper, D. (2013). Posttraumatic Stress Disorder. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da08
179. Kennedy, S. H. (2008). Core symptoms of major depressive disorder: relevance to diagnosis and treatment. Dialogues in Clinical Neuroscience. https://doi.org/10.31887/dcns.2008.10.3/shkennedy
180. Khadse, V. S. C. (2022). Free Papers Compiled. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.341792
181. Khan, M. G., Thangapandi, M., Kurian, S. M., Suresh, V. N., Nagendra, D., Kushwah, A. S., & Yezdani, U. (2020). Epidemiological Study and review on Chronic Insomnia; Neurological Disease. International Journal of Current Research and Review. https://doi.org/10.31782/ijcrr.2020.121813
182. Kintz, P., Villain, M., Cirimele, V., Goullé, J., & Ludes, B. (2002). [Crime under the influence of psychoactive drugs: the problem of the duration of detection].. PubMed.
183. Kocsis, J. H., & Brody, B. D. (2013). Chronic depression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781139175869.010
184. Koo, S. K. (2018). Depression Status in Korea. Osong Public Health and Research Perspectives. https://doi.org/10.24171/j.phrp.2018.9.4.01
185. Kotade, K. B., Pandit, B. S., Gaware, V. M., Dolas, R. T., Dhamak, K. B., Somwanshi, S. B., Nikam, V. K., & Khadse, A. N. (2011). KNOWING DEPRESSION AND PHARMACOLOGICAL, NON-PHARMACOLOGICAL APPROACHES FOR ITS TREATMENT.
186. Koychev, I., & Ebmeier, K. P. (2016). Anxiety in older adults often goes undiagnosed.. PubMed.
187. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część I. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.27
188. Ksiądzyna, D., Merwid‐Ląd, A., Matuszewska, A., Grotthus, B., & Szeląg, A. (2019). Objawy odstawienia wybranych leków. Część II. Medycyna Rodzinna. https://doi.org/10.25121/mr.2019.22.1.33
189. Lejoyeux, M., & Adès, J. (1993). [Psychiatric emergencies in acute alcoholic intoxication].. PubMed.
190. Lemogne, C., Pitron, Jy, R., Limosin, F., & Cathébras, P. (2019). What attitude towards a patient with somatoform disorder?. PubMed.
191. Lečić-Toševski, D. M., Pejović-Milovančević, M., Popović-Deušić, S., & Šušić (2007). [Psychiatric aspects of sleep].. PubMed.
192. Lim, H., Cho, Y. S., & Kim, H. J. (2008). Case Reports : A Case of Gluteal Myonecrosis Aggravated after Discharge by Intoxication with Several Drugs Including Tricyclic Antidepressants (TCA). 대한응급의학회지.
193. Loosen, P. T. (1994). Cushingʼs Syndrome and Depression. The Endocrinologist. https://doi.org/10.1097/00019616-199409000-00008
194. Láinez, M. J. A., Casado, A. G., & Gascon, C. D. (2013). Optimal management of severe nausea and vomiting in migraine: improving patient outcomes. Patient Related Outcome Measures. https://doi.org/10.2147/prom.s31392
195. Maceira, E., Lesar, T. S., & Smith, H. S. (2012). Medication related nausea and vomiting in palliative medicine.. PubMed. https://doi.org/10.3978/j.issn.2224-5820.2012.07.11
196. Macenski, C. L. (2021). Recurrent episodes of binging and purging. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0024
197. Macenski, C. L. (2021). Recurrent episodes of intense fear, shortness of breath, racing heart, and sweating. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0014
198. Machado, C. F. A., & Siqueira, E. C. D. (2022). Uma abordagem geral do Transtorno de Estresse Pós-Traumático: revisão de literatura. Revista Eletrônica Acervo Médico. https://doi.org/10.25248/reamed.e10939.2022
199. Madan, A., Frueh, B. C., Fowler, J. C., Stomberg, S., Bradshaw, M. R., Kelly, K. R., Weinstein, B., Luttrell, M., Danner, S. G., & Beidel, D. C. (2020). “Operator syndrome”: A unique constellation of medical and behavioral health-care needs of military special operation forces. The International Journal of Psychiatry in Medicine. https://doi.org/10.1177/0091217420906659
200. Mahato, T. K., Ojha, S. K., Singh, V., & Parihar, S. P. S. (2021). Addiction withdrawal syndrome: Needs medications, education, counselling &amp; support. World Journal of Advanced Research and Reviews. https://doi.org/10.30574/wjarr.2021.12.2.0573
201. Mahon, K., Arnold, R. W., & Koller, H. P. (2007). Symptomatic Convergence Insufficiency. Journal of Pediatric Ophthalmology & Strabismus. https://doi.org/10.3928/01913913-20070701-12
202. Malin, H., & Saleh, F. M. (2007). Paraphilias: Clinical and Forensic Considerations.
203. Manber, R., Ong, J. C., & Carlyle, E. (2008). Diagnostic Tools for Insomnia. CRC Press eBooks. https://doi.org/10.3109/9781420019926-6
204. Manniche, C., Hauge, E., Voss, A., Mašić, D., Johannsen, F. E., Johannsen, F. E., Voss, A., Mašić, D., Mašić, D., Voss, A., & Johannsen, F. E. (2018). Patient med rygsmerter. Research Portal Denmark.
205. Marchand, D. K., & Argáez, C. (2021). Codeine for Acute Extremity Pain [Internet].
206. Martinez, J. D. (2020). El paciente con cefalea por uso excesivo de medicamentos en urgencias. Acta neurológica colombiana. https://doi.org/10.22379/24224022314
207. Mazza, M., Faia, V., Paciello, N., Marca, G. D., & Mazza, S. (2002). Sleep disorders in childhood: a review.. PubMed.
208. McGillion, M., O’Keefe-McCarthy, S., & Carroll, S. (2013). Self-Management Training for Chronic Stable Angina: Theory, Process, and Outcomes. InTech eBooks. https://doi.org/10.5772/54635
209. McGowan, K., March, K., & Finch, C. K. (2021). The Hunger for Mirtazapine: A Discontinuation Syndrome. Journal of Pain & Palliative Care Pharmacotherapy. https://doi.org/10.1080/15360288.2021.1883183
210. McQuillan, R. (2020). Symptoms other than pain. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0065
211. Meade, M. S. (1993). Beriberi. Cambridge University Press eBooks. https://doi.org/10.1017/chol9780521332866.077
212. Mecarelli, O., & Vicenzini, E. (2019). Brain Death. Clinical Electroencephalography. https://doi.org/10.1007/978-3-030-04573-9_47
213. Medina, S., & Fernando, D. (2019). Caso Christopher : El deseo, de deseo imposible en la neurosis obsesiva..
214. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). [Clinical practice guideline. Diagnosis and treatment of insomnia in the elderly].. PubMed.
215. Medina-Chávez, J. H., Fuentes-Alexandro, S., Gil-Palafox, I. B., Adame-Galván, L., Solís-Lam, F., Sánchez-Herrera, L. Y., & Narváez, F. S. (2014). Diagnóstico y tratamiento del insomnio en el adulto mayor.
216. Mellero, D. (2007). Ansiedade em situações de convívio social em idosos.
217. Mercês, T. M. D. (2019). Controle hidroeletrolítico e respostas cardiovasculares à injeção central de angII, carbacol e hiperosmolaridade plasmática em ratos com epilepsia induzida por pilocarpina.
218. Messina, G., Franzini, A., Cecchini, A. P., & Leone, M. (2016). ONS and DBS for the Treatment of Chronic Cluster Headache. InTech eBooks. https://doi.org/10.5772/64482
219. Metropulos, J. T., Goldstein, B. R., & Hodapp, B. (2022). Recognition and Treatment Challenges of Acute Clozapine Withdrawal Syndrome: A Case Report. Cureus. https://doi.org/10.7759/cureus.25765
220. Michel, B. (2020). Posttraumatic stress disorder concerning the end of the covid-19 lockdown: A mini review. Archives of Depression and Anxiety. https://doi.org/10.17352/2455-5460.000044
221. Michie, S. (2002). CAUSES AND MANAGEMENT OF STRESS AT WORK. Occupational and Environmental Medicine. https://doi.org/10.1136/oem.59.1.67
222. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395
223. Mikkelsen, M. E., & Iwashyna, T. J. (2020). Persistent problems and recovery after critical illness. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0395_update_001
224. Mirawati, D. K. (2018). Managing antiepileptic drug, Starting, Changing and Stopping AED’s.
225. Mitchell, P. B., Goodwin, G. M., Johnson, G. F., & Hirschfeld, R. M. A. (2008). Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disorders. https://doi.org/10.1111/j.1399-5618.2007.00559.x
226. Miyasato, K. (2013). [Psychiatric and psychological features of nicotine dependence].. PubMed.
227. Montgomery, S., Bebbington, P., Cowen, P. J., Deakin, J., Freeling, P., Hallström, C., Katona, C., King, D. S., Leonard, B., Levine, S., Phanjoo, A. L., Peet, M., Thompson, C. M., & Thompson, C. M. (1993). Guidelines for treating depressive illness with antidepressants: A statement from the British Association for Psychopharmacology. Journal of Psychopharmacology. https://doi.org/10.1177/0269881193007001041
228. Mospan, C. M. (2021). Chapter 14: Headache. The American Pharmacists Association eBooks. https://doi.org/10.21019/9781582123592.ch14
229. Moukaddam, N., & Shah, A. A. (2016). Treatment-Resistant Depression: An Overview. Psychiatric Annals. https://doi.org/10.3928/00485713-20160215-01
230. Moura, G. S., Neves, L. M. T., Giorelli, A. S., Florido, P., & Gomes, M. D. M. (2013). Transtornos do sono: visão geral Sleep disorders: overview.
231. Mueller‐Pfeiffer, C., & Wittmann, L. (2013). Preliminary Investigation of the Reliability and Validity of the German Version of the State Scale of Dissociation (SSD). Journal of Traumatic Stress Disorders & Treatment. https://doi.org/10.4172/2324-8947.1000106
232. Mut, E. A., Pălădoiu, C., & Stănescu, M. (2021). Somatoform and conversion disorders as psychological defences. Journal of Educational Sciences & Psychology. https://doi.org/10.51865/jesp.2021.1.19
233. Nagpal, K., Rao, N. P., Behere, R. V., Venkatasubramanian, G., Varambally, S., & Gangadhar, B. N. (2013). Details always tell a big story: Importance of physical symptoms in evaluation of secondary causes of depression. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.12010
234. Nakayama, H., Mihara, S., Sakuma, H., Kitamura, D., & Higuchi, S. (2014). SY08-3 * CO-MORBIDITY OF INTERNET ADDICTION. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agu052.39
235. Narindra, S. K., & Musabiq, S. (2019). Combining Methods of CBT and Progressive Relaxation for Treating Primary Insomnia: A Case Study. https://doi.org/10.2991/iciap-18.2019.38
236. Naveed, S., Faquih, A. E., & Chaudhary, A. M. D. (2018). Pregabalin-associated Discontinuation Symptoms: A Case Report. Cureus. https://doi.org/10.7759/cureus.3425
237. Neufeld, K. J., Needham, D. M., Oh, E. S., Wilson, L. M., Nikooie, R., Zhang, A., Koneru, M., Balagani, A., Singu, S., Aldabain, L., & Robinson, K. A. (2019). Antipsychotics for the Prevention and Treatment of Delirium. https://doi.org/10.23970/ahrqepccer219
238. Newman, L. C., Levin, M., Singh, R. B. H., & Michael, R. L. (2022). Refractory Chronic Migraine. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190842130.003.0024
239. Niesink, R. J., & Laar, M. V. (2013). Does Cannabidiol Protect Against Adverse Psychological Effects of THC?. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2013.00130
240. Noel, N., Seibell, P., Nadeau, J., & Storch, E. (2016). Treating just-right symptoms in geriatric obsessive-compulsive disorder. Indian Journal of Psychiatry. https://doi.org/10.4103/0019-5545.196700
241. Ojimba, C., Isidahome, E. E., Odenigbo, N., Umudi, O. D., & Olayinka, O. (2019). Catatonia in major depressive disorder: diagnostic dilemma. A case report. Journal of Psychology & Clinical Psychiatry. https://doi.org/10.15406/jpcpy.2019.10.00651
242. Oliveira, S., Canha, J., & Pereira, S. P. (2013). 2362 – Is it a prodrome of psychosis? Or is it naanxious disorder? A case report. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77202-x
243. Olmos-López, A., Ibarra-Aguilar, J., Cornelio-Nieto, J. O., Ocaña-Hernández, L. A., Márquez-Amaya, M. A., Luna-López, N. A., Reséndiz-Aparicio, J. C., & Rodríguez‐Leyva, I. (2019). Clinical guideline: status epilepticus in children and adults. DELETED. https://doi.org/10.24875/rmn.m19000031
244. Onda, K., Yukawa, T., Sakaue, M., Tsuboya, R., Inoue, E., & Someya, T. (2021). Withdrawal from long‐term use of caffeinated drinks can cause schizophrenia‐like symptoms: A case report. Psychiatry and Clinical Neurosciences. https://doi.org/10.1111/pcn.13199
245. Orme, S., & Harari, D. (2020). Bladder and bowels. Oxford University Press eBooks. https://doi.org/10.1093/med/9780198746690.003.0060
246. Os, J. V., Praag, H. M. V., & Kloet, E. R. D. (2004). Stress, the brain and depression. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544422.010
247. Otsuka, K., Kato, S., Abe, T., SUGIYAMA, H., Watanabe, Y., Kobayashi, T., & Okajima, Y. (2002). [Classification of long-term clinical course of 'atypical psychosis': a 20-year follow-up study at a medical school hospital].. PubMed.
248. PADMAWATI, N. N., Ardani, I. G. A. I., Ariyani, A., Ariani, P., & Purnamasidhi, ‪. A. W. (2021). Psychopharmaceutical Therapy and Supportive Psychotherapy for COVID-19 Patients with Depression. International Journal of Medical Reviews and Case Reports. https://doi.org/10.5455/ijmrcr.covid-19-psychopharmaceutical-therapy-172-1608192666
249. Pagel, J., Pandi‐Perumal, S. R., & Monti, J. M. (2018). Treating insomnia with medications. Sleep Science and Practice. https://doi.org/10.1186/s41606-018-0025-z
250. Pallesen, S., Olsen, O. K., Eide, E. M., Nortvedt, B., Grønli, J., Larøi, F., Nordmo, M., & Glomlien, F. E. (2018). Sleep deprivation and hallucinations. A qualitative study of military personnel. Military Psychology. https://doi.org/10.1080/08995605.2018.1478561
251. Panahi, S., & Tremblay, A. (2018). Sedentariness and Health: Is Sedentary Behavior More Than Just Physical Inactivity?. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2018.00258
252. Paredes, D. F. D., Farfán, J. C. P., Orellana, J. M. F., & Legarda, A. A. B. (2019). Trastorno disfórico premenstrual. RECIAMUC. https://doi.org/10.26820/reciamuc/3.(1).enero.2019.199-217
253. Partinen, M., Huutoniemi, A., Kajaste, S., Lagerstedt, R., Markkula, J., Mäkinen, E., Paakkari, I., Partonen, T., Polo, P., Saarenpää‐Heikkilä, O., Seppälä, M., Kukkonen-Harjula, K., & Tuunainen, A. (2016). [Update on Current Care Guideline: Insomnia].. PubMed.
254. Passantino, A., & Masucci, M. (2016). Congenital and inherited neurologic diseases in dogs and cats: Legislation and its effect on purchase in Italy. Veterinary World. https://doi.org/10.14202/vetworld.2016.437-443
255. Paulin, L. F. R. D. S., Reis, E. F. D., & Rodrigues, E. P. (2008). Síndrome de descontinuação dos antidepressivos.
256. Paw, H., & Shulman, R. (2014). Management of status epilepticus. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9781316182673.042
257. Pergolizzi, J. V., LeQuang, J. A., & Bisney, J. (2018). Cannabinoid Hyperemesis. Medical Cannabis and Cannabinoids. https://doi.org/10.1159/000494992
258. Pergolizzi, J. V., Taylor, R. J., LeQuang, J. A., Gould, E. M., & Raffa, R. B. (2019). Treating Insomnia in Older Adult Patients: Limiting Benzodiazepine Use. Pharmacology &amp Pharmacy. https://doi.org/10.4236/pp.2019.103010
259. Persson, P. B., & Persson, A. B. (2016). Fatigue. Acta Physiologica. https://doi.org/10.1111/apha.12756
260. Petit, J., & Sansone, R. A. (2011). A Case of Interdose Discontinuation Symptoms With Venlafaxine Extended Release. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.11l01140
261. Petzke, F., Tölle, T. R., Fitzcharles, M., & Häuser, W. (2021). Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS Drugs. https://doi.org/10.1007/s40263-021-00879-w
262. Peña, M. A. M. (2013). Síndrome de sobreentrenamiento. IATREIA.
263. Phu, T., Remmers, A., Schytz, H. W., Schankin, C. J., Nelson, S. E., Obermann, M., Hansen, J. M., Sinclair, A. J., Gantenbein, A. R., & Schoonman, G. (2018). Red and orange flags for secondary headaches in clinical practice. Neurology. https://doi.org/10.1212/wnl.0000000000006697
264. Pothmann, R. (2008). Kopfschmerzen bei Kindern – Diagnostik und Therapie unterschiedlicher Kopfschmerzformen. Notfall & Hausarztmedizin. https://doi.org/10.1055/s-0028-1098954
265. Pothmann, R. (2020). Migräne in der Pubertät. Zeitschrift für Komplementärmedizin. https://doi.org/10.1055/a-1201-1975
266. Prabu, M. I. J., & Sharma, C. P. (2021). STRESS AND HYPERTENSION. IDC International Journal. https://doi.org/10.47211/idcij.2021.v08i01.009
267. Pramawati, N. N., Mastiningsih, P., Ekajayanti, P. P. N., & Purnamayanthi, P. P. I. (2025). Pengaruh Akupresur Terhadap Penurunan Skala Insomnia Pada Lansia Di Posyandu Lansia Banjar Puseh Desa Angantaka. Sakti Bidadari (Satuan Bakti Bidan Untuk Negeri). https://doi.org/10.31102/bidadari.2025.8.1.18-25
268. Provini, F., Lombardi, C., & Lugaresi, E. (2005). Insomnia in Neurological Diseases. Seminars in Neurology. https://doi.org/10.1055/s-2005-867074
269. Pytell, J. D., & Rastegar, D. A. (2025). Cannabinoids. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197796207.003.0009
270. Pétursson, H. (1994). The benzodiazepine withdrawal syndrome. Addiction. https://doi.org/10.1111/j.1360-0443.1994.tb03743.x
271. Quintero, J. M. B., Castellanos, A., & Santos, L. S. D. L. (2018). Efectividad de una intervención pre-quirúrgica de enfermería; en ansiedad de pacientes sometidos a colecistectomía del Hospital General Regional No.1 Vicente Guerrero de Acapulco, 2017.
272. Rahmawati, R. (2022). Menurunkan gejala kecemasan pada gangguan kecemasan umum dengan cognitive therapy. Procedia Studi Kasus dan Intervensi Psikologi. https://doi.org/10.22219/procedia.v10i4.19184
273. Raj, R., Kumar, H., & Murad, A. (2022). A Double Blind, Randomized, Placebo-Controlled Clinical Study of the Nutraceutical Ashwagandha in the Form of Vedaan Ashwagandha KSM 66 Capsules as an Antioxidant, Energy Booster, Nervine Tonic, Anti-Stress and Aphrodisiac in General and Specific Chronic Ailments. International Journal of Research in Medical Sciences & Technology. https://doi.org/10.37648/ijrmst.v14i01.013
274. Ramesh, D., Schlosburg, J. E., Wiebelhaus, J. M., & Lichtman, A. H. (2011). Marijuana Dependence: Not Just Smoke and Mirrors. ILAR Journal. https://doi.org/10.1093/ilar.52.3.295
275. Ramos, B. R. M., Martins, F. S., & Osório, E. (2022). Psychotic Cannabis Withdrawal: A Clinical Case. Cureus. https://doi.org/10.7759/cureus.31465
276. Raspe, H. (1994). [Work capacity--a central category of practical social medicine].. PubMed.
277. Reinares, M., Martínez‐Arán, A., & Vieta, E. (2019). Psychoeducation for Patients and Family Members. Cambridge University Press eBooks. https://doi.org/10.1017/9781108589802.004
278. Rempel, D., Hegmann, K. T., & Meister, R. (2018). 1632f Varied criteria for work-related upper extremity disorders in united states. https://doi.org/10.1136/oemed-2018-icohabstracts.732
279. Riaz, Y., & Sergi, C. (2021). Feeding Disability In Children.
280. Robinson, C. P., & Hocker, S. E. (2019). Status Epilepticus. Oxford University Press eBooks. https://doi.org/10.1093/med/9780190862923.003.0098
281. Robinson, P., Wicksell, R. K., & Olsson, G. (2022). ACT en pacientos con dolor crónico. ABA España eBooks. https://doi.org/10.26741/978-84-09-43990-4_13
282. Rossi, G., & Beck, M. (2020). A Little Dab Will Do: A Case of Cannabis-Induced Psychosis. Cureus. https://doi.org/10.7759/cureus.10311
283. ROY, R., Kumar, S. P., & Kishor, M. (2022). A Case of Trichotillomania With Comorbid Depression And Anxiety. Digital Journal of Clinical Medicine. https://doi.org/10.55691/2582-3868.1004
284. Roy‐Byrne, P. (2008). Cannabis Withdrawal Syndrome: Reefer Madness?. Journal watch. https://doi.org/10.1056/jp200810270000004
285. Ruiz, C. B., Torralbo, M. B., Garcia, R. R., Llobet, A. H., Fernández, I. A., Nielsen, N. P., Landeo, A. R., Ramírez, M. M., Fuentes, D. G., Soler, M. A., & Cañete, J. (2020). Psicosis dual y cariprazina. Caso clínico. LIBRO COMUNICACIONES. https://doi.org/10.17579/sepd2020p141
286. Ríos, C. G., Sánchez, M. V., Campos, M. L. P., Lozano, C. F., & Montañés, P. M. (2021). Mitos y realidades sobre la enuresis en pediatría.. Revista Sanitaria de Investigación.
287. Sabljić, V., Ružić, K., & Rakun, R. (2011). Venlafaxine withdrawal syndrome.. PubMed.
288. Sadikin, A., & Linda, N. (2018). PENYALAHGUNAAN NARKOBA DAN PSIKOTROPIKA DI KALANGAN REMAJA.
289. Sandi, C. (2013). Stress and cognition. Wiley Interdisciplinary Reviews Cognitive Science. https://doi.org/10.1002/wcs.1222
290. Sari, R. A. (2020). Literature Review: Depresi Postpartum. Jurnal Kesehatan. https://doi.org/10.26630/jk.v11i1.1586
291. Sawant, N., & Thakurdesai, A. (2018). CASE REPORT: SLEEP DEPRIVATION PRESENTING AS ACUTE PSYCHOSIS. Indian Journal of Case Reports. https://doi.org/10.32677/ijcr.2018.v04.i02.020
292. Saxena, C. (2022). A Case Report on Generalized Anxiety Disorder through Medical Cannabis. Journal of Case Reports and Scientific Images. https://doi.org/10.22271/27080056.2022.v4.i1a.45
293. Schep, L. J., Slaughter, R. J., Glue, P., & Gee, P. (2020). The clinical toxicology of cannabis.. PubMed.
294. Schwerthöffer, D., Fatke, B., & Förstl, H. (2020). Dilemmasituation: Nächtlicher Unruhezustand beim älteren Patienten.
295. Scotton, W. J., Hill, L. J., Williams, A., & Barnes, N. M. (2019). Serotonin Syndrome: Pathophysiology, Clinical Features, Management, and Potential Future Directions. International Journal of Tryptophan Research. https://doi.org/10.1177/1178646919873925
296. Seemüller, F., Allwang, C., & Beraldi, A. (2019). Ist Burnout eine Folge des Arbeitslebens?. Nervenheilkunde. https://doi.org/10.1055/a-0876-9848
297. Sejdić, E., Malandraki, G. A., & Coyle, J. L. (2018). Computational Deglutition: Using Signal- and Image-Processing Methods to Understand Swallowing and Associated Disorders [Life Sciences]. IEEE Signal Processing Magazine. https://doi.org/10.1109/msp.2018.2875863
298. Sewart, A. R., & Craske, M. G. (2018). Panic Disorder and Agoraphobia. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190492243.003.0013
299. Shakhar, K., & Fleisig, D. (2013). How to Cope with Stress and Depression in Women with Recurrent Miscarriage. https://doi.org/10.1002/9781118749012.ch13
300. Sharp, L. K., & Lipsky, M. S. (2002). Screening for depression across the lifespan: a review of measures for use in primary care settings.. PubMed.
301. Shirley, E. A., Hudspeth, L. J., & Maynard, J. R. (2018). Managing Sports-related Concussions From Time of Injury Through Return to Play. Journal of the American Academy of Orthopaedic Surgeons. https://doi.org/10.5435/jaaos-d-16-00684
302. Simbolon, N. Y., Sitorus, T. R., Meliala, T. L., & Waruwu, P. (2020). TINJAUAN KRIMINOLOGI TERHADAP ANAK YANG MELAKUKAN TINDAK PIDANA PENYALAHGUNAAN NARKOTIKA. JURNAL ILMIAH SIMANTEK.
303. Sinha, S., Moss, A. J., & Calkins, H. (2007). The etiology of sudden death. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544828.014
304. Smith, D. K., Sadler, K. P., & Benedum, M. (2019). Febrile Seizures: Risks, Evaluation, and Prognosis.. PubMed.
305. Smitherman, T. A., & Rogers, D. G. (2020). Insomnia. The Wiley Encyclopedia of Health Psychology. https://doi.org/10.1002/9781119057840.ch181
306. Snaith, P. (1994). Anxiety Control Training. Advances in Psychiatric Treatment. https://doi.org/10.1192/apt.1.2.57
307. Soyuer, F., & Kepenek-Varol, B. (2019). Quality of life and pain. International Journal of Family & Community Medicine. https://doi.org/10.15406/ijfcm.2019.03.00140
308. Spielberger, C. D. (2022). Anxiety. Routledge eBooks. https://doi.org/10.4324/9781003261919-7
309. Stahl, S. M. (1993). Mixed anxiety and depression: clinical implications.. PubMed.
310. Starling, A. J., Choe, M., & Giza, C. C. (2024). How Many Concussions Are Too Many Before an Athlete Should Retire?. Routledge eBooks. https://doi.org/10.4324/9781003526131-26
311. Steffens, D. C., Blazer, D. G., & Beyer, J. L. (2013). Mood Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781615370016.mt05
312. Stevens, M. (1993). Tension-type headaches.. PubMed.
313. Stewart, S. M. (2013). Depression. The Encyclopedia of Cross‐Cultural Psychology. https://doi.org/10.1002/9781118339893.wbeccp158
314. Strain, J. J., Klipstein, K., & Newcorn, J. H. (2008). Adjustment Disorders. Psychiatry. https://doi.org/10.1002/9780470515167.ch81
315. Stringer, J. D. (2016). Gender and Sexual Health: Sexual Dysfunction.. PubMed.
316. Stubbe, D. (2007). Child and adolescent psychiatry : a practical guide. Lippincott Williams & Wilkins eBooks.
317. Stäubli, M. (1993). [Panic attacks].. PubMed.
318. Surova, G., Ulke, C., Schmidt, F., Hensch, T., Sander, C., & Hegerl, U. (2020). Fatigue and brain arousal in patients with major depressive disorder. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-020-01216-w
319. Söderpalm, B. (2002). Anticonvulsants: aspects of their mechanisms of action. European Journal of Pain. https://doi.org/10.1053/eujp.2001.0315
320. Tagaya, H., Murayama, N., & Hakamata, Y. (2012). [Definitions and clinical classifications of sleep disorders].. PubMed.
321. Tanamal, M. A. (2016). PENGARUH STRES DAN NYERITERHADAP RESIKO ADIKSI MORFINPADA HEWAN COBA MENCIT(Mus musculus).
322. Tang‐Wai, D. F., Josephs, K. A., & Petersen, R. C. (2005). Alzheimer's disease: overview. Cambridge University Press eBooks. https://doi.org/10.1017/cbo9780511544873.029
323. Taylor, M. E., & Whitney, J. (2021). Impaired Cognition and Falls. Cambridge University Press eBooks. https://doi.org/10.1017/9781108594455.009
324. Taylor, S. M., & Beckmann, D. (2021). An adolescent with new-onset inattention. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197577479.003.0028
325. Teja, N., Gummadi, O. D., Devi, B. V., & Pavani, N. (2020). Evaluation of Depressant Activity on Mansoa alliacea on Rats. Acta Scientific Pharmaceutical Sciences. https://doi.org/10.31080/asps.2020.04.0617
326. Tepper, D. (2013). Cefalea Como Resultado de Conmoción Cerebral en Los Deportes. Headache The Journal of Head and Face Pain. https://doi.org/10.1111/head.12153
327. Thomas, H. (1993). Psychiatric Symptoms in Cannabis Users. The British Journal of Psychiatry. https://doi.org/10.1192/bjp.163.2.141
328. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. DeckerMed Family Medicine. https://doi.org/10.2310/fm.13043
329. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/cannabis.13043
330. Thompson, A., & Weber, A. (2021). Alcohol and Drug Withdrawal Syndromes and Their Clinical Management. https://doi.org/10.2310/psych.13043
331. Timo, P. (2021). Hallucination: A Mental Illness. Clinical Psychiatry. https://doi.org/10.36648/2471-9854.21.7.81
332. Toro, V. D., Aedo, K., & Urrejola, P. (2021). Trastorno de Evitación y Restricción de la Ingesta de Alimentos (ARFID): Lo que el pediatra debe saber. Andes pediatrica. https://doi.org/10.32641/andespediatr.v92i2.2794
333. Torres, C. F., & Zubizarreta‐Macho, Á. (2022). Mandibular advancement appliances to treat apnea: an update of the most used currently. A systematic review and meta-analysis. https://doi.org/10.37766/inplasy2022.11.0034
334. Touloumis, C. (2021). Treatment resistant depression: Challenges and therapeutic choices. Psychiatriki. https://doi.org/10.22365/jpsych.2021.047
335. Treiman, D. M. (1993). Generalized Convulsive Status Epilepticus in the Adult. Epilepsia. https://doi.org/10.1111/j.1528-1157.1993.tb05902.x
336. Trill, M. D. (2013). Anxiety and sleep disorders in cancer patients. European Journal of Cancer Supplements. https://doi.org/10.1016/j.ejcsup.2013.07.009
337. Trivedi, K., Kataria, L., & Patel, D. (2020). A COMPARATIVE STUDY EVALUATING THE DEPRESSIVE SYMPTOMS AND FUNCTIONAL OUTCOME IN PATIENTS TREATED WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS V/S SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS AS ANTIDEPRESSANT AGENTS IN MAJOR DEPRESSIVE DISORDER.
338. Turner, R. M., & Elson, E. (1993). Sleep disorders. Steroids cause sleep disturbance.. BMJ. https://doi.org/10.1136/bmj.306.6890.1477-d
339. Uddin, M., Zaman, F., Jahan, K., Tarafder, M., Hossain, A., & Rahman, F. (2018). Reccurent episodes of vomiting and hyperpigmentation---Addison,s disease, a case report. TAJ Journal of Teachers Association. https://doi.org/10.3329/taj.v29i2.39111
340. Undevia, N. S. (2013). Women and Excessive Daytime Sleepiness. Humana Press eBooks. https://doi.org/10.1007/978-1-62703-324-4_12
341. Valdez, J. M. (2013). [Status epilepticus in childhood].. PubMed.
342. Vanderschuren, L. J. M. J. (2008). Neurobehavioral Mechanisms of Compulsive Drug Seeking. https://doi.org/10.1093/oso/9780195300550.003.0009
343. Vandvik, I. H., & Skjeldal, O. H. (1994). [Conversion disorders in children and adolescents. A multidisciplinary approach].. PubMed.
344. Vanin, J. R. (2008). Brief Psychiatric History and Mental Status Examination. Humana Press eBooks. https://doi.org/10.1007/978-1-59745-263-2_2
345. Viader, F. (2019). L’ictus amnésique idiopathique : un syndrome amnésique exemplaire. Revue de neuropsychologie. https://doi.org/10.3917/rne.111.0070
346. Vicente, M. O., Gutiérrez, L. E. J. F., & Oves, M. I. R. (2011). ALCOHOLISMO CONSECUTIVO AL TRASTORNO DE PÁNICO. DOAJ (DOAJ: Directory of Open Access Journals).
347. Vilibić, M., Jukić, V., Vidović, A., & Brečić, P. (2013). Cobalamin deficiency manifested with seizures, mood oscillations, psychotic features and reversible dementia in the absence of typical neurologic and hematologic signs and symptoms: a case report.. PubMed.
348. Vrhovski, D. (2016). Sindrom pretreniranosti u trkača.
349. Wahyuningsih, S., Nurun, N., Ainul, A., Rendra, R., & Dwiki, D. (2020). Relaksasi Nafas Dalam Terhadap Tingkat Kecemasan Pada Lansia Yang Menderita Hipertensi Di RT 03 RW 09 Kelurahan Slipi Palmerah Jakarta Barat. JURNAL KREATIVITAS PENGABDIAN KEPADA MASYARAKAT (PKM). https://doi.org/10.33024/jkpm.v3i2.3194
350. Wakerley, B. R. (2020). Medication-overuse headache: painkillers are not always the answer. British Journal of General Practice. https://doi.org/10.3399/bjgp20x707777
351. Wallace, D. J., & Wallace, J. B. (2002). Are You Sure It’s Really Fibromyalgia?. Oxford University Press eBooks. https://doi.org/10.1093/oso/9780195147537.003.0025
352. Wand, G. S. (2008). The influence of stress on the transition from drug use to addiction.. PubMed.
353. Wehrman, E. C. (2022). Grief/Bereavement. The International Encyclopedia of Health Communication. https://doi.org/10.1002/9781119678816.iehc0883
354. Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2013). 2824 – Acute psychosis and buprenorphine withdrawal: abrupt vs. progressive could make a difference. European Psychiatry. https://doi.org/10.1016/s0924-9338(13)77409-1
355. Weiss, B., Clarkson, T. W., & Simon, W. (2002). Silent latency periods in methylmercury poisoning and in neurodegenerative disease.. Environmental Health Perspectives. https://doi.org/10.1289/ehp.02110s5851
356. Wiebe, D. J., Comstock, R. D., & Nance, M. L. (2011). Concussion research: a public health priority. Injury Prevention. https://doi.org/10.1136/ip.2010.031211
357. Wiederhold, B. K., Garmon, E. H., & O'Rourke, M. C. (2019). Nerve Block Anesthesia.
358. Wiglusz, M. S., Cubała, W. J., Nowak, P. M., Jakuszkowiak‐Wojten, K., Landowski, J., & Krysta, K. (2013). Sibutramine-associated psychotic symptoms and zolpidem-induced complex behaviours: implications for patient safety.. PubMed.
359. Williams, D., & Loshak, H. (2019). Strength-based Exercise for Chronic Non-Cancer Back Pain: A Review of Clinical Effectiveness.
360. Wilson, D. S., & Nutt, P. D. J. (2013). Insomnia. Oxford University Press eBooks. https://doi.org/10.1093/med/9780199674558.003.0003
361. Winters, K. C., & Ingwalson, A. (2022). Internalizing and Related Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0006
362. Winters, K. C., & Ingwalson, A. (2022). Substance Use Disorders. Oxford University Press eBooks. https://doi.org/10.1093/med-psych/9780190678487.003.0005
363. Wiśniewski, M., Anand, J. S., Chodorowski, Z., & Kosińska-Tomczyk, H. (2007). [Tiagabine overdose--report of two cases].. PubMed.
364. Wong, M. K., Darvishzadeh, A., Maler, N. A., & Bota, R. G. (2016). Five Supplements and Multiple Psychotic Symptoms: A Case Report. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.15br01856
365. Woo, C. H., & Kim, S. (2014). Effectiveness of the Military Mental Health Promotion Program. Journal of Korean Academy of Nursing. https://doi.org/10.4040/jkan.2014.44.6.717
366. Woutersen-Koch, H., Smout, A. J. P. M., Flik, C. E., Hulshof, C., Wit, N. J. D., & Horst, H. E. V. D. (2012). Multidisciplinaire richtlijn prikkelbaredarmsyndroom.
367. Woutersen-Koch, H., Smout, A. J. P. M., Flik, C. E., Hulshof, C., Wit, N. J. D., & Horst, H. E. V. D. (2013). [Multidisciplinary guideline irritable bowel syndrome].. PubMed.
368. Wright, S. L. (2020). Benzodiazepine Withdrawal. Oxford University Press eBooks. https://doi.org/10.1093/med/9780197517277.003.0008
369. Yarlagadda, A. R., Brown, A. B., & Clayton, A. H. (2007). Onset of Obstructive Sleep Apnea After Initiation of Psychotropic Agents. The Primary Care Companion to The Journal of Clinical Psychiatry. https://doi.org/10.4088/pcc.v09n0611h
370. Yates, S. J., Ahuja, N., Gartside, S. E., & McAllister‐Williams, R. H. (2011). Serotonin syndrome following introduction of venlafaxine following withdrawal of phenelzine: implications for drug washout periods. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/2045125311413497
371. Yee, B. J., Liu, P. Y., Phillips, C. L., & Grunstein, R. R. (2013). Neuroendocrine aspects of sleep apnea. CRC Press eBooks. https://doi.org/10.3109/9781420020885-16
372. Yudofsky, S. C., Silver, J., & Anderson, K. (2013). Aggressive Disorders. American Psychiatric Publishing eBooks. https://doi.org/10.1176/appi.books.9781585625154.da10
373. Yustiana, A. V., & Aryani, L. N. A. (2019). Gangguan psikotik akibat penggunaan ganja (cannabis): studi kasus. Medicina Journal. https://doi.org/10.15562/medicina.v50i2.123
374. Zhang, K., & Hashimoto, K. (2018). An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2019.1554434
375. Çelik, A. S., & Pasinlioğlu, T. (2013). KLİMAKTERİK DÖNEMDE YAŞANAN SEMPTOMLAR VE HEMŞİRENİN ROLÜ.
376. Ďurdík, P., Olek, F., ov, U. J., an, T. T., & Bánovčin, P. (2020). Young and exhausted. Authorea (Authorea). https://doi.org/10.22541/au.159294140.04360533